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resumo 
 
A artrite reumatóide (AR) é uma doença reumática crónica, inflamatória e 
imuno-mediada. A erosão óssea é uma das características da fisiopatologia 
da AR e está associada à gravidade da doença. As erosões ósseas em 
pacientes com AR resultam de um metabolismo ósseo alterado devido, em 
parte, a osteoclastogénese (o processo pelo qual as células precursoras da 
linhagem de monócitos se diferenciam em osteoclastos) e a atividade 
osteoclástica excessivas. Num estudo recente, observou-se uma expressão 
variável de RNAs longos não codificantes (lncRNAs) durante a 
osteoclastogénese no ratinho, sugerindo um papel fisiológico dos lncRNAs 
neste processo. Em pacientes com AR, vários estudos observaram até à data 
uma expressão alterada de lncRNAs em tipos celulares críticos da 
fisiopatologia da doença, como leucócitos mononucleares do sangue 
periférico e sinoviócitos ativados tipo-fibroblastos. No entanto, nenhum estudo 
examinou, até ao momento, a expressão de lncRNAs em monócitos e 
osteoclastos de pacientes com AR. Este trabalho visou abordar esta questão 
analisando a expressão de um painel de 8 lncRNAs (GAS5, NEAT1, Meg3, 
DANCR, HOTAIR, Meg9, H19 e Sox2OT) em monócitos e osteoclastos de 
pacientes com AR, artrite inicial e controlos saudáveis. Os doentes foram 
recrutados no Serviço de Reumatologia do Hospital de Santa Maria, Centro 
Académico de Medicina de Lisboa. Dadores emparelhados por idade e sexo 
foram usados como controlos saudáveis. Foi colhido sangue heparinizado, a 
partir do qual, se isolaram células mononucleadas de sangue periférico 
(PBMCs) por centrifugação em gradiente de densidade. Os monócitos 
aderentes foram depois diferenciados in vitro em osteoclastos por um 
protocolo de diferenciação de 21 dias. RNA total foi extraído de monócitos e 
osteoclastos, para posterior análise da expressão de lncRNAs por PCR 
quantitativo em tempo real (RT-qPCR). Estudou-se a expressão de lncRNAs 
para dezassete indivíduos, incluindo 7 pacientes com artrite reumatóide 
estabelecida, 3 pacientes com artrite inicial e 7 dadores saudáveis. Observou-
se um número substancialmente superior de osteoclastos em pacientes com 
artrite inicial face ao obtido para controlos saudáveis. Observámos um 
aumento da expressão de NEAT1 e GAS5, e uma diminuição da expressão 
de DANCR, em monócitos de pacientes com AR estabelecida. Por outro lado, 
observou-se uma expressão aumentada de NEAT1 e diminuída de GAS5 e 
DANCR em osteoclastos de pacientes com artrite inicial. Não foram 
encontradas diferenças estatisticamente significativas. Os resultados obtidos 
são consistentes com um potencial osteoclastogénico aumentado em 
monócitos periféricos de pacientes com artrite inicial e, portanto, com um 
metabolismo ósseo alterado.  Globalmente, os resultados de expressão de 
lncRNAs sugerem que os lncRNAs testados possam ter um papel na 
osteoclastogénese na AR, atendendo aos seus níveis de expressão alterados 
em monócitos de pacientes com artrite inicial e com AR. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
keywords 
 
Rheumatoid arthritis, bone erosion, monocytes, osteoclasts, 
osteoclastogenesis, long non-coding RNAs (lncRNAs). 
abstract 
 
Rheumatoid arthritis (RA) is a chronic inflammatory immune-mediated 
rheumatic disease. Bone erosion is one of the hallmarks of RA 
pathophysiology and is associated with disease severity. Bone erosions in RA 
patients result from an imbalanced bone metabolism due, in part, to excessive 
osteoclastogenesis (the process by which precursor cells of the monocyte 
lineage differentiate into osteoclasts) and osteoclastic activity. Variable 
expression of long non-coding RNAs (lncRNAs) has been observed during 
mouse osteoclastogenesis, suggesting a physiologic role for lncRNAs in the 
process. In RA patients, lncRNA expression has been further shown to be 
altered in cellular types critical for its pathophysiology, like peripheral blood 
mononuclear leukocytes and activated fibroblast-like synoviocytes, in 
comparison to healthy controls. However, no study has yet examined lncRNA 
expression in monocytes and osteoclasts of RA patients. This work aims to 
address this question by analyzing the expression of a panel of 8 lncRNAs 
(GAS5, NEAT1, Meg3, DANCR, HOTAIR, Meg9, H19, and Sox2OT) in 
monocytes and osteoclasts of early arthritis patients, established RA patients 
and healthy controls. Both groups of patients were recruited at the 
Rheumatology Department, Hospital de Santa Maria, Lisbon Academic 
Medical Centre, Portugal. Age and sex matched donors were used as healthy 
controls. Heparinized blood was collected from each participant. Peripheral 
blood mononuclear cells (PBMCs) were isolated from whole blood samples by 
density gradient centrifugation. Adherent monocytes were in vitro 
differentiated into osteoclasts by a 21-day differentiation protocol. Total RNA 
was extracted from both monocytes and osteoclasts, for further analysis of 
lncRNA expression by real-time quantitative PCR (RT-qPCR). LncRNA 
expression analysis was performed for seventeen subjects, including 7 
established rheumatoid arthritis patients, 3 early arthritis patients and 7 
healthy donors. In vitro osteoclastogenesis produced a substantially higher 
number of osteoclasts in early arthritis patients, when compared to healthy 
controls. From our lncRNA panel, only GAS5, NEAT1, and DANCR presented 
a measurable expression in all tested samples. Our results showed an 
increased expression of NEAT1 and GAS5 along with a decreased expression 
of DANCR in monocytes of established RA patients, in comparison to those of 
healthy controls. An increased expression of NEAT1 along with a decreased 
expression of GAS5 and DANCR was observed in osteoclasts of early arthritis 
patients, when compared to those of healthy controls. No statistically 
significant differences were found for both analyses. Our data are consistent 
with an increased osteoclastogenic potential of peripheral monocytes of early 
arthritis patients, and thus, with an imbalanced bone metabolism in this 
pathological condition. Overall, our results prompted us to suggest that the 
lncRNAs here analyzed may in fact play a role in osteoclastogenesis in RA, 
as an altered lncRNA expression was observed in monocytes of early arthritis 
and established RA patients, when compared to healthy controls.  
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INTRODUCTION  
 
1. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory and immune-mediated disease [1,2]. It is an 
idiopathic disease (of unknown cause), that can be defined as a clinical syndrome spanning several 
disease subsets, with multiple pathogenic mechanisms [1–3]. The hallmark of RA is systemic 
inflammation, with persistent symmetric peripheral polyarthritis and structural damage of cartilage 
and bone tissue, leading to joint swelling, loss of function and stiffness [2]. The hypersensitivity 
reaction associated with disease pathogenesis in RA is mediated by immune complexes (type III 
reaction), and the main autoantibodies involved are rheumatoid factor (RF) and anti-citrullinated 
protein antibody (anti-ACPA) [4,5]. RA patients can be subdivided into two subtypes designated 
“seropositive” and “seronegative”, with seropositivity being defined as the presence of serum 
elevations of the autoantibodies RF and/or ACPAs [6].  
The pain and progressive deterioration of joint function, along with increased comorbidity, have a 
high impact on health and quality of life of RA patients.  In severe cases, the ability to work can be 
compromised [7]. Different criteria can be applied to assess disease severity in RA: disease activity, 
extraarticular manifestations and joint destruction [8]. Concerning this, the Disease Activity Score 
based on 28 joints (DAS28) is one of the most widely used tools to assess disease activity in RA 
patients [9]. 
 
 
1.1. Epidemiology 
Worldwide prevalence of RA is of around 1%, with a significant variation of the disease incidence 
and prevalence among different populations [10]. In Portugal, the total prevalence of RA is of 0.7%, 
with a four-fold higher prevalence in women than in men (1.2% and 0.3% respectively) [11]. It is the 
most common form of chronic inflammatory arthritis [12]. A systematic review by Minichiello et al., 
described a trend toward a decline in the incidence of RA [8]. However, while some studies support 
such decrement [13,14], others report an increasing trend in the incidence of RA in the general 
population [15,16].  
Patients with rheumatoid arthritis present a life expectancy decreased by 3 to 10 years when 
compared with the general population, along with a 50%-54% increased risk of premature mortality 
[7]. Higher severity of the disease is associated with a higher risk of death [7]. Cardiovascular 
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diseases, respiratory diseases, and infections are among the primary causes of death in RA patients 
[7,17]. The increased risk for infection in RA patients may be attributed to the impaired immune 
function in RA or an effect of immunosuppressive therapy. Death by an infection in RA patients is 
often due to respiratory infection or pneumonia [17]. Recent trends show no significant reduction 
in mortality in RA patients worldwide [7]. However, information about the mortality rates of 
observational studies differ. Some studies show higher mortality in RA patients [18,19], while others 
report that mortality in patients with RA was not different from that of the general population 
[20,21].  
Several studies show a decrement in disease activity over time, based on a decline of DAS28 values, 
suggesting a decrease in RA severity in most recent cohorts [22–24]. Regarding overall 
extraarticular manifestations, there is no consensus. Some authors report a decrease [25], while 
others describe no significant changes over time [26]. A study from the UK, in a stable well-defined 
population, monitored for 15 years, reported a decrease in the incidence of systemic rheumatoid 
vasculitis [27]. On the other hand, the need for joint surgery reflects the degree of joint destruction 
[8]. Increased severity of disease leads to an increased need for joint surgery. Some studies report 
a decline in the severity of joint destruction, in RA patients, over time [28,29]. Regarding the need 
for joint surgery, several authors indicate a significant reduction in both the risk and the incidence 
of joint surgery [30–32].  
These varying results might be explained by differences in treatment or different types of cohorts 
and follow-up time [33]. Nevertheless, evidence indicates a decrease in severity over time, with 
fewer extraarticular manifestations and lower disease activity, along with a diminished need for 
surgery to treat joint destruction, and less severe radiological changes [8]. Van Nies et al., reported 
an improvement in the outcome of early RA patients over the last decade, based on lower rates of 
joint destruction and higher remission rates [20]. The authors hypothesized that current treatment 
strategies, namely the use of disease modifying anti-rheumatic drugs (DMARDs), combination 
therapies and tight control of disease activity, have been having a positive impact on the survival of 
RA patients, thus reflected in a reduction of the mortality risk in RA [20].  
 
 
1.2 Characteristics and Pathophysiology 
Rheumatoid arthritis comprises different disease subsets that involve several immuno-
inflammatory cascades, with predominant features varying from patient to patient [2]. 
Nevertheless, all the involved cascades in RA lead towards a final common pathway characterized 
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by persistent synovial inflammation (hyperplasia) and associated damage to articular cartilage and 
underlying bone tissue [2]. The characteristic hyperplastic joint present in RA, with several 
inflammatory cellular infiltrations, is represented in Figure 1.  
Even though joint involvement is the hallmark of this disease, RA is an organ nonspecific (systemic) 
immune-mediated disease since extraarticular pathologic lesions or manifestations can be found, 
including fatigue, subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, 
vasculitis, and hematologic abnormalities [12]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pathophysiological mechanisms that have been proposed for the development of RA involve a 
complex interplay between different cells, genetic and environmental factors, triggers, and chance 
[34]. Both T and B cells and the action of pro-inflammatory cytokines play key roles in the 
pathophysiology of RA [35]. Tumor necrosis factor alpha (TNF-) and interleukin (IL-6) are regarded 
as the cytokines most directly implicated in RA, although IL-1 and IL-17 may also play an important 
role in the disease process [35–37]. Prominent T-cell infiltrate in RA patients suggests these cells 
Figure 1 - Cartoon representation of a normal joint (left) and a rheumatoid arthritis joint (right). 
Adapted from Strand et al., 2007 [265]. 
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are key participants in the acute inflammatory features of RA [1]. Nevertheless, increasing evidence 
suggests that a variety of innate effector cells, such as monocytes and macrophages, are also closely 
involved in the development of synovial inflammation in RA. In fact, massive infiltration of activated 
monocytes/macrophages are frequently observed in synovial membranes of RA patients. These are 
a major source of cytokines (such as TNF-, IL-1β, IL-8, and GM-CSF) in the inflamed joints [38]. 
The initial milestone for RA pathogenesis onset is thought to be the activation of the innate immune 
response, including the activation of dendritic cells by exogenous material and autologous antigens 
[35]. Antigen-presenting cells, including dendritic cells, macrophages and activated B cells, present 
arthritis-associated antigens to T cells [35,39]. These T cells are upregulated by various 
lymphokines, including interleukin 2 (IL-2) and interferon γ (IFNγ). Upon stimulation, T cells induce 
activation of macrophages, B cells, fibroblasts, and osteoclasts [38,39]. In turn, B lymphocytes 
express various cell-surface molecules, including antigen receptor immunoglobulin and 
differentiation antigens, such as CD20 and CD22. Upon differentiation, they turn into plasma cells 
that secrete antibodies, including autoantibodies to IgG (rheumatoid factor), to citrullinated 
peptides such as vimentin, fibrinogen, or cyclic citrullinated peptide (CCP) and to rheumatoid 
arthritis antigen (RA33) [42,43]. On the other hand, the formation of immune complexes by 
autoantibodies can increase the production of proinflammatory cytokines such as TNF-. In fact, 
the occurrence of autoantibodies RF and anti-CCP are associated with severe rheumatoid arthritis 
and can be used as an effective strategy for identifying patients with RA at high risk for poor 
outcome [44]. When activated, B cells also serve as APCs, inducing T cell activation, and potentially 
leading to the perpetuation of the immune-mediated proinflammatory response [42]. Besides cells 
of the innate and adaptive immune system, several other inflammatory cell populations infiltrate 
the synovial membrane in rheumatoid arthritis patients [34,35,45].  
The in situ pathological occurrences within the synovial inflammation include activation of 
endothelial cells, along with neovascularization and increased presence of fibroblast-like 
synoviocytes (FLSs). These synoviocytes are highly activated and secrete inflammatory mediators, 
cytokines and matrix metalloproteinases (MMPs) [46,47]. MMPs are enzymes that can degrade the 
components of the extracellular matrix of the joint [48]. By secreting MMPs into the synovial fluid, 
and probably by direct invasion, fibroblast-like synoviocytes can destroy cartilage and play a role in 
bone destruction [46,49]. Nevertheless, bone erosions occur mainly via activated osteoclasts. Bone 
erosions in RA patients result from an imbalanced bone metabolism due, in part, to excessive 
osteoclastogenesis and osteoclastic activity, that leads to increased bone resorption by osteoclasts, 
and inadequate bone formation by osteoblasts [50–52]. Besides being responsible for bone 
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resorption, osteoclasts are key players in the complex crosstalk between bone and immune cells, 
that leads to the perpetuation of the inflammatory environment in joints of RA patients [53–55]. 
The role of osteoclasts in physiological bone metabolism and in RA pathogenesis will be discussed 
further ahead.   
All the above-mentioned events and complex cross-talk of immune and inflammatory modulators 
promote influx, expansion, and activation of cells in the synovium, ultimately leading to the 
immunoinflammatory and destructive response of rheumatoid arthritis, clinically presented as joint 
swelling and joint and bone destruction [56,57]. However, the precise hierarchy of events remains 
enigmatic. It is nowadays understood that multiple and redundant pathophysiological mechanisms 
contribute to RA [56,57]. 
 
 
1.3 Diagnostic and Treatment 
Diagnostic of RA is mostly clinical, along with a combination of laboratory tests, and imaging 
methods. The most recent criteria to the diagnosis of rheumatoid arthritis are the 2010 American 
College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) criteria [58], 
and their application is due to be made by the physician regarding each patient’s individual 
circumstances. These guidelines are aimed at identifying rheumatoid arthritis among patients that 
recently present synovitis (inflammation of a synovial membrane) in at least one joint, in the 
absence of an alternative diagnosis that better explains the synovitis. For patients to be diagnosed 
with RA, they need to achieve a total score of at least 6 (of a possible 10) within 4 evaluation 
domains [58,59]. These domains include the following: (1) the number and site of involved joints, 
(2) serologic abnormalities (presence of rheumatoid factor or anti-citrullinated peptide/protein 
antibody), (3) elevations of inflammatory markers (erythrocyte sedimentation rate and/or C-
reactive protein [CRP]), and (4) the duration of symptoms [58]. The criteria for the evaluation of 
disease progression are the 2012 ACR Disease Activity Measures [60]. 
To treat RA patients, there are multiple drugs currently available for use. These can be non-steroidal 
anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) or adjunctive 
agents such as corticosteroids, and analgesics [61–63]. Most of the NSAIDs are designed to target 
and suppress prostaglandins (PGs), inflammatory mediators, through inhibition of the 
cyclooxygenase (COX) enzymes [61]. These can lead to renal, hepatic, and cardiovascular toxicity 
with long-term use in RA patients [61]. Within the NSAIDs, there are many different drugs, such as 
Ibuprofen, Aspirin, and Naproxone [61].  
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DMARDs are a class of antirheumatic drugs which can be divided into two sub-categories: non-
biological (synthetic) and biological [62]. Among non-biological DMARDs, methotrexate (MTX) has 
been the gold standard for the past few decades in the treatment of RA patients [62,63]. Although 
its exact mechanism has not been fully defined, MTX can block cytokine production and modulate 
specific matrix metalloproteinases (MMPs) levels [64,65].  
The introduction of biological DMARDs (bDMARDs) dramatically changed the treatment and 
outcome of RA, as they are significantly more effective than non-biologic treatments in improving 
physical function in RA patients [66]. These drugs include monoclonal antibodies targeting tumor 
necrosis factor (TNF)-α (anti-TNF-α), IL-6 receptor (anti-IL6R), IL-1 receptor (anti-IL1R) and other 
inhibitors of cytokines and immune cells that play a major role in promoting RA pathogenesis [67]. 
As previously described, cytokines play a fundamental role in the pro-inflammatory milieu occurring 
within the synovium of affected joints in RA patients [36,68]. Among these, TNF-α and IL-6 are 
considered the most relevant and constitute the therapeutic targets of several drugs for 
rheumatoid arthritis [69]. These drugs can directly inhibit these cytokines, or interfere with receptor 
binding, or both. Up to date, a total of five anti-TNF drugs have entered clinical use, namely 
infliximab (IFX), adalimumab (ADA), etanercept (ETC), golimumab (GLM), and certolizumab pegol 
(CZP) [70]. Infliximab (IFX) was the first TNF-α inhibitor to be administered in RA patients. Both 
infliximab, adalimumab, and golimumab are monoclonal antibodies anti-TNF-α. Certolizumab pegol 
is a humanized monovalent Fab antibody fragment linked to polyethylene glycol (PEG) [70]. 
Etanercept was the first biological DMARD to be approved for treating RA and is a recombinant 
fusion protein in which the extracellular domain of TNF receptor II is fused to the Fc-portion of IgG1 
[70,71]. IL-6 has also been the focus of great interest in RA. This cytokine in presumed to play key 
roles in the context of the pathogenesis of rheumatoid arthritis:  activation of T cells, macrophages 
and osteoclasts, and induction of antibody production by B cells [37,72–74]. Tocilizumab is a 
monoclonal antibody to the IL- 6 receptor, that targets the actions of this cytokine [75,76].  
However, despite the range of available treatments, several unmet needs remain. There is a lack of 
predictive biomarkers of prognosis, therapeutic response, and toxicity. Importantly, current 
synthetic and biological DMARDs therapies sometimes fail or produce only partial responses. In 
addition, sustained remission in RA patients is rarely achieved and requires ongoing pharmacologic 
therapy [77].  
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1.4 Risk Factors  
Multiple genetic and environmental factors have been associated with an increased risk of 
developing rheumatoid arthritis [78]. In RA, altered gene expression is present in both circulating 
immune cells and synovial tissues [79]. 
The genetic factors can include susceptibility genes such as HLA-DRB1, which shows the strongest 
association with RA, in particular with ACPA positive RA [80]. Most HLA DRB1 alleles that predispose 
to RA (HLA DRB1*01, *04, and *10 alleles) share a specific amino acid sequence in their peptide-
binding region. This sequence similarity might implicate the involvement of these shared epitope 
alleles in presenting arthritis-related peptides. Some studies have reported that these alleles may 
preferably present citrullinated peptides, which could explain the strong association with ACPA 
positive RA  [81,82]. RA patients expressing two HLA-DRB1*04 alleles are at elevated risk for 
nodular disease, major organ involvement and increased need for surgery related to joint 
destruction [83]. Furthermore, HLA and non-HLA genes may discriminate anti-cyclic citrullinated 
peptide (anti-CCP) antibody–positive and anti–CCP–negative RA groups [84].  
Genome-wide association studies (GWAS) have expanded the number of validated RA risk loci, 
identifying additional alleles related to RA risk beyond HLA-DRB1 shared epitope alleles [84]. Single-
nucleotide polymorphism genotyping across the MHC has identified additional alleles related to RA 
risk, including those found on the conserved A1-B8-DR3 (8.1) haplotype and those near the HLA-
DRB1 gene. Some of the relevant single-nucleotide polymorphisms (SNPs) linked to RA 
pathogenesis include RAF1, STAT4, CTLA4, IRF5, CCR6, PTPN22, IL23R, and PADI4 [85–87]. Among 
these, some of the most relevant include PTPN22 and PADI4 [86,87]. Like HLA-DRB1, PTPN22 is 
mostly associated with ACPA positive RA. It encodes a tyrosine phosphatase involved in T and B cell 
signaling [87]. PADI4 encodes for an arginine deiminase responsible for the posttranslational 
conversion of arginine into citrulline residues. Besides being associated with RA susceptibility, the 
PADI4 haplotype is also mainly associated with ACPA positive RA [86].  
Among the multiple environmental, lifestyle, and behavioral risk factors already studied, cigarette 
smoking is regarded as the most strongly and consistently associated with the development of RA, 
presenting a clear dose-response  [88–90]. As well as the susceptibility genes, environmental 
factors such as smoking are most strongly associated with the seropositive RA phenotype [91]. It is 
estimated that smoking is responsible for around 35% ACPA positive RA cases. Furthermore, 55% 
of ACPA positive RA can be attributable to smoking, in individuals carrying two copies of the HLA-
DRB1 shared epitope [91].  
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2. Monocytes 
Human monocytes represent 5 % – 10% of the blood leucocytes and their half-life in the vascular 
compartment is around 1 – 3 days. Monocytes in blood have some typical morphological features 
such as the irregular shape of the cell and its nucleus, high cytoplasm-to-nucleus ratio, and light 
blue cytoplasm [92–94].  These cells originate in the bone marrow from hematopoietic stem cells 
(HSCs). They are then released into the peripheral blood, where they circulate. These circulating 
monocytes give rise to tissue-resident macrophages and specialized cells, such as dendritic cells 
(DCs) and osteoclasts [93]. Monocytes have important roles in both innate and adaptive immunity, 
primarily functioning in immune defense, inflammation, and tissue remodeling, in both 
homeostasis and inflammation. During inflammation, monocytes circulate through the blood and 
extravasate into inflamed tissues, where they differentiate into macrophages, generally 
maintaining the same inflammatory phenotype [95]. 
Monocytes are categorized into three major subsets, according to the expression of CD14 (the LPS 
co-receptor) and CD16 (the low-affinity receptor for the Fc region of IgG): classical CD14++CD16− 
that constitute about 90% of circulating monocytes, and intermediate CD14++CD16+ and non-
classical CD14+CD16+ that together constitute the remaining 10% [96,97]. The first two populations 
of monocytes share many features, including a high capacity for phagocytosis and proinflammatory 
cytokine production. Classical monocytes, the dominant blood population, express CCR2, a receptor 
involved in mobilization from the bone marrow (BM) and recruitment to inflammatory sites, which 
is the main function of classical monocytes [98,99]. In contrast, non-classical monocytes present a 
reduced CCR2 but elevated CX3CR1 surface expression, which is needed for patrolling blood vessels 
and migrating into resting tissues [96,100]. The population of intermediate monocytes expresses 
both CCR2 and CX3CR1 on intermediate level and shows the highest HLA-DR expression [101]. 
 
 
2.1. Role of monocytes in the pathophysiology of rheumatoid arthritis 
Infiltration of monocytes along with T and B cells and the exacerbated presence and activity of 
macrophages and osteoclasts into the synovial tissue and production of inflammatory mediators 
typify the immunopathology of RA [102]. These accumulating activated monocytes massively 
infiltrate inflammatory sites (synovial membranes) of RA patients and present a significantly 
increased expression of CD16 on their surface and produce TNF- in response to TLR stimulation 
[103–107]. The impact of the monocytic lineage in determining the immune response is substantial 
and these cells interfere with both the innate and adaptive immunity [108]. For example, in RA, 
Analysis of lncRNAs expression in monocytes and osteoclasts of rheumatoid arthritis patients 
Inês Abrunhosa Amaral 
39 
 
monocytes present in inflamed joints have been shown to induce the development of Th17 cells, 
thus contributing to the amplification of inflammation. In fact, T cell - monocyte contact is involved 
in cartilage destruction and cytokine production [109,110]. Therefore, targeting monocyte-derived 
cytokines such as tumour necrosis factor (TNF), IL-1, IL-6 or even monocyte - T cell interaction might 
be a therapeutic strategy for controlling inflammation in RA patients non-responsive to classical 
DMARDs [111]. Approaches to depletion of monocytes using specific antibodies could prevent their 
presence in the synovial tissue and thus, attenuate inflammation [112,113]. 
In RA patients, the frequencies of classical, intermediate and non-classical blood monocytes are 
altered, when compared to healthy controls [114–116]. CD14+CD16+ monocytes (non-classical) are 
increased in the blood of RA patients, which might contribute to the persistent joint inflammation 
of RA [117]. These monocytes display properties for antigen presentation and inflammatory 
characteristics upon activation [118]. Increased expression of CD16 in monocytes was observed in 
patients with active disease and increased counts of tender and swollen joints. CD16 expression on 
RA blood monocytes was augmented in vitro by IL-10, M-CSF, and TGF-β1 [117]. These pieces of 
evidence suggest that monocytes are key players in RA pathogenesis, contributing the perpetuation 
of the inflammatory milieu observed in the joints of RA patients. However, it is still unknown 
whether and how the altered frequency of monocytes subsets in RA patients affects the role of 
monocytes and/or macrophages in the pathogenesis of RA.  
In addition to their central role in modeling inflammation, monocytes can be pinpointed as the 
origin of pathological bone erosion in RA, due to their excessive differentiation into osteoclasts 
[119]. As such, monocytes may thus constitute ideal targets to modulate osteoclastogenesis in 
inflammation and RA.  
 
 
3. Osteoclasts 
An osteoclast can be described as a tissue-specific macrophage of the bone, able to degrade bone 
tissue by polarized secretion of proteolytic enzymes such as cathepsin K and acid, which hydrolyzes 
and solubilize the organic and inorganic components of bone [50,120]. In fact, in physiological 
conditions, the osteoclast is the only cell type capable of resorbing bone [120]. Mature osteoclasts 
are fused polykaryons (multinuclear cells) arising from multiple (up to 10–20) individual cells [50].  
Osteoclastogenesis is the process by which hematopoietic precursor cells of the 
monocyte/macrophage lineage differentiate into osteoclasts [50,120]. In particular, peripheral 
blood monocytes (PBMs) constitute the main source of precursors of osteoclasts, like as with other 
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tissue macrophages [121,122]. PBMs leave the peripheral circulation by margination in capillaries 
and migration into the extravascular pool. Osteoclasts arise from these migrating monocytes by in 
situ proliferation of macrophage precursors and further differentiation in tissues [93]. For such 
processes, two major cytokines are required: the macrophage colony stimulating factor (MCSF) and 
the receptor activator of NF-kB ligand (RANKL) supplied mostly by osteoblasts and/or osteocytes 
[50,120]. M-CSF binds to its receptor c-FMS, (cellular-feline McDonough strain sarcoma virus 
oncogene homologue, or CSF-1 receptor, or CD115), which in turn induces the expression of RANK 
on monocytes. RANKL expression by synovial fibroblasts is induced by pro-inflammatory cytokines 
such as TNF-a, IL-1, IL-6, and IL-17 [123].  The RANK/RANKL ligand-receptor complex is a crucial 
intervenient in osteoclast differentiation and activation. RANKL is a necessary factor for the 
differentiation of osteoclasts and functions as both survival factor and activator [124]. Its 
physiological inhibitor is osteoprotegerin (OPG) [124]. Osteoblasts are the main source of RANKL. 
However, it can be expressed by synovial cells, activated T cells, mature B cells and NK cells. RANKL 
is a mediator of differentiation, survival, and activation of osteoclasts and its expression is 
upregulated by TNF, IL-1, IL-6, and IL-17 [124]. Overall, osteoclastogenesis and osteoclast activation 
are regulated, both positively and negatively, by at least 24 gene or loci [50]. Among these are as 
well cytokines, produced by monocytes, with important effects on osteoclast differentiation, 
activation, and apoptosis [121].  
 
 
3.1. Role of osteoclasts in the pathophysiology of rheumatoid arthritis  
Osteoclasts play a critical role in skeletal homeostasis by regulating bone resorption. However, in 
RA, they excessively populate chronically inflamed joints, resorbing the bone in an exacerbated way 
and creating localized skeletal defects, the so-called bone erosions [125]. Chronic inflammation 
appears to be a key mediator for both local and systemic bone loss in RA patients [124]. In fact, 
inflammation itself might trigger bone resorption by osteoclasts [126]. It has been reported that 
the high levels of pro-inflammatory cytokines prevalent in the synovial fluid of affected joints in RA 
patients are associated with osteoclast-mediated focal bone erosion at the margins of these joints 
[127]. Pro-inflammatory cytokines are potent mediators of bone loss and correlate with greater 
disease activity in RA patients. They can enhance osteoclastogenesis in inflamed joint and bone, 
acting on osteoclasts, osteoblasts, and their precursors, by inducing RANKL expression 
[124,128,129].  
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RA patients present increased numbers of osteoclast progenitors in the peripheral blood, exhibiting 
an enhanced ability to differentiate into osteoclasts when compared to those of matched healthy 
controls [130]. The extensive infiltration of monocytes in the synovial tissue of inflamed joints in RA 
patients leads to an increased number of osteoclasts, as these function as osteoclast precursors 
and provide specific molecular signals that drive osteoclast formation, as previously stated [131]. 
Overall, osteoclasts play a critical role in bone destruction in RA and could represent a therapeutic 
target for RA [132]. 
The role of monocytes and osteoclasts in the pathophysiology of rheumatoid arthritis is 
represented in  Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Bone metabolism 
Bone homeostasis is modulated by both inflammation and immunological events. The concept of 
osteoimmunology was coined a few years ago to account for the interplay between the bone and 
immune systems [123,133]. During life, bone undergoes modeling and remodeling to grow or 
change shape. The main cells involved in bone remodeling are osteoblasts and osteoclasts, whose 
Figure 2 - Cartoon representation of the role of monocytes and osteoclasts in RA pathogenesis. 
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functions are tightly coupled. Additional cells involved in bone metabolism are osteocytes and the 
bone lining cells [134].  
The osteoblast is a specialized bone-forming cell derived from mesenchymal stem cells (MSCs). 
Osteoblasts produce bone by synthesis and secretion of type I collagen, that makes up the major 
bone matrix protein. They also participate in the mineralization of the newly formed bone [135]. As 
previously stated, osteoclasts are the cells capable of resorbing bone. For osteoclasts to be 
activated and bone resorption to commence, non-polarized, mature osteoclasts must bind to the 
bone matrix. When osteoclasts bind to bone, they become polarized [120]. Osteocytes are the most 
abundant and long-lived cells in bone. They comprise 90-95% of the total bone cells and have a 
lifespan of up to 25 years. Osteocytes originate from osteoblasts that have undergone terminal 
differentiation during bone formation and subsequently have been engulfed by the unmineralized 
osteoid. Following mineralization, these entombed cells become osteocytes [136]. Its functions 
include monitoring bone quality and stress, as well as coordinate remodeling through membrane-
bound and secreted factors [120,137]. Bone lining cells are quiescent flat-shaped osteoblasts that 
cover the bone surfaces, where neither bone resorption or bone formation occurs [138]. 
 
 
4.1. Normal bone metabolism: modeling and remodeling 
Bone is a complex tissue, undergoing continuous remodeling to heal damage, grow and maintain 
calcium and phosphate homeostasis [120,139,140]. The human bone is composed of trabecular 
bone, the fine bony network hosting the bone marrow, and cortical bone, the dense bony shell that 
provides structural support in weight-bearing regions [51]. A healthy bone metabolism relies on a 
delicate balance between bone formation by osteoblasts and bone resorption by osteoclasts 
[120,139,140]. The concerted and sequential actions of both osteoclasts and osteoblasts in the 
process of bone remodeling has been termed the basic multicellular unit (BMU) [139–141].  
It is important to note that bone remodeling differs from bone modeling. Bone modeling is the 
process by which the generation and maintenance of the shape of bone during skeletal growth 
occur, allowing bones to change shape or size in accordance to physiologic influences or mechanical 
forces [142,143]. This process lasts from the beginning of skeletal development in fetal life until the 
end of the second decade of life, which is when the longitudinal growth of the skeleton is completed 
[140]. In turn, bone remodeling is a continuous process, occurring throughout life, with the purpose 
of maintaining strength and mineral homeostasis in the bone tissue [144]. Osteoclastic resorption 
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is tightly coupled to the osteoblastic bone formation during the bone remodeling cycle 
[139,145,146]. 
The remodeling occurs within the BMU and is a process defined by five phases: activation, 
resorption, reversal, formation, and termination [140,146]. The bone lining cells separate from the 
underlying bone and form a raised cover that encases each BMU, exposing the bone surface at the 
site to be remodeled and creating a unique environment for coupled resorption–formation [147]. 
Each active BMU consists of bone-resorbing osteoclasts covering the newly exposed bone surface, 
resorbing the old bone and preparing the surface for the deposition of replacement bone. Following 
immediately behind, the osteoblasts secrete and deposit unmineralized bone osteoid  [148,149]. 
The orderly arrangement of the cells within the BMU is critical for correct remodeling, ensuring the 
correct sequence of the phases of the process [148,149].  
The first phase of the bone remodeling cycle is the activation phase, which is characterized by the 
recruitment of osteoclasts [140,146]. The initiating signal for remodeling can be either hormonal or 
mechanic and is supposed to be detected by the osteocytes. In fact, osteocytes are key players in 
the bone remodeling cycle modulation [137,150,151]. Succeeding the detection of the signal occurs 
the retraction of the bone lining cells and the digestion of the endosteal membrane by collagenase. 
Alongside with this, occurs the recruitment of precursor cells from the monocyte/macrophage 
hematopoietic lineage, which are recruited from circulation and are activated at the site [152–154]. 
Multiple mononuclear cells fuse to form multinucleated preosteoclasts that migrate and attach to 
the bone surface. These develop and terminally differentiate in activated osteoclasts after binding 
to the bone matrix and thus form bone-resorbing compartments, secreting acid and lytic enzymes 
to break down the bone matrix [50,155].  
The second phase of the bone remodeling cycle is the resorption phase when the osteoclasts resorb 
bone. This phase lasts approximately two to four weeks during each remodeling cycle  [140,146]. 
Osteoclasts generate an acidic microenvironment in the attachment zone, secreting hydrogen ions 
that drop the pH as low as 4.5 within the bone-resorbing compartment [156]. These acidic 
conditions might help mobilize bone mineral and could favor the action of secreted lysosomal 
proteinases in the degradation of collagen [156–158]. The degradation of the collagen-rich bone 
matrix by osteoclasts occurs through the secretion of specialized proteinases, such as matrix 
metalloproteinases (MMPs) and cathepsin K  [157,159]. At last, to ensure that excess resorption 
does not occur, the resorption phase is terminated by osteoclasts programmed cell death [160]. 
The third phase of the bone remodeling cycle is the reversal phase, where the osteoclasts undergo 
apoptosis and the osteoblasts are recruited. This phase lasts approximately four to five weeks in 
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each bone remodeling cycle [140,146]. Reversal phase is characterized by a shift from bone 
resorption to bone formation when osteoclasts are replaced by osteoblast-lineage cells which 
initiate bone formation [139,145]. However, the multitude of coupling signals between osteoclasts 
and osteoblasts that lead to this phase is not yet fully understood. Current understanding suggests 
that the release of osteogenic signals from the osteoclasts might initiate the coupling activity of the 
reversal phase [161,162]. There is evidence that osteoclasts (OCs) can produce many different 
molecules that affect the osteoblast lineage, both positively and negatively. These include OC-
derived cell surface signals, OC-derived soluble signals and resorption-derived soluble signals [162]. 
Cells of the osteoblast lineage also appear to play an essential role in the concerted effort in bone 
remodeling, regulating bone-resorbing activity by osteoclasts and coupling resorption with the 
formation during the reversal phase [163]. These regulatory signals and coupling factors, produced 
by either osteoclasts or cells from the osteoblast lineage, can be cytokines and/or regulatory 
receptors on the cells surface, such as IL-6, BMP-2, TGF-β, insulin-like growth factor (IGF), 
prostaglandin E2 (PGE2), receptor activator of NF-kB (RANK)/RANK ligand (RANKL) and 
osteoprotegerin (OPG)/OPG ligand (OPGL), functioning for instance in the ephrin-Eph bidirectional 
signaling between osteoblasts and osteoclasts [163–167]. Summarizing, the recently resorbed bone 
surface is prepared for the deposition of new bone matrix, and complex signaling occurs to couple 
resorption to bone formation, leading to the replacement of osteoclasts by osteoblast-lineage cells 
which initiate bone formation [161].  
The fourth phase of the bone remodeling cycle is the formation phase when new bone formation 
occurs. This phase can last approximately up to four to six months [140,146]. Osteoblasts synthesize 
new bone matrix (osteoid), rich in type I collagen, filling the cavities left behind by osteoclastic bone 
resorption [168].  As the new bone matrix is gradually mineralized it gives origin to new bone. This 
process is called bone mineralization, whereby hydroxyapatite crystals are deposited among 
collagen fibrils. This process is regulated by controlling systemic levels of calcium and phosphate 
concentrations, along with the local concentration of calcium and phosphate within extracellular 
matrix vesicles [169–172].  
The fifth and final phase of the bone remodeling cycle is the termination phase when mineralization 
of the bone matrix is fully completed. The bone enters in a quiescent state, and the amount of bone 
formed equals the amount resorbed. At this phase, osteoblasts undergo apoptosis, change into 
bone-lining cells or become buried within the newly formed bone matrix and terminally 
differentiate into osteocytes  [140,146].  
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Bone remodeling is a crucial mechanism for normal bone metabolism and to maintain overall bone 
homeostasis. It involves a great number of cells and complex regulatory mechanisms [148,149,152–
154]. Deregulation of this mechanism and involved cells is associated with numerous skeletal 
disorders such as osteoporosis and most importantly, RA [173,174]. Regarding this latter disease, 
an increased osteoclastogenesis and deregulated osteoclastic activity at bone resorption phase 
gives origin to bone erosions [51,175]. Therefore, osteoclasts activity, differentiation, and its 
regulatory mechanisms present as a key field to be studied in RA. The following topic will focus on 
this matter.  
 
 
4.2. Altered bone metabolism in rheumatoid arthritis: bone erosion and osteoclasts  
Bone erosion is one of the hallmarks of RA pathophysiology and is associated with disease severity, 
leading to a poor outcome and reduced quality of life [51,176]. It represents an independent risk 
factor for generalized osteopenia and osteoporosis [51]. The typical feature observed on plain 
radiographs of RA patients is the erosion of periarticular cortical bone. However, both types of bone 
(trabecular and cortical) are targeted for erosion in RA. Resulting from an imbalance in bone 
metabolism, bone erosions in RA patients are due to an excessive osteoclastic activity that leads to 
increased bone resorption by osteoclasts, and inadequate bone formation by osteoblasts [50,51]. 
In RA, bone damage and degradation are executed by osteoclasts while fibroblast-like synoviocytes 
are responsible for cartilage degradation [176]. Initially involving the cortical bone, the articular 
bone erosion leads to the destruction of the natural barrier between the surrounding tissue and 
the intertrabecular spaces of the bone marrow cavity [51]. Increased bone resorption activity in RA 
patients has been reported with osteoclasts originating from peripheral blood monocytes [130]. 
This means that the osteoclasts responsible for bone erosions in RA derive mainly from monocyte 
progenitors that infiltrate the synovial membrane [177]. In fact, the rheumatoid pannus has been 
shown to contain mononuclear cells exhibiting tartrate-resistant acid phosphatase (TRAP) activity, 
one of the markers for osteoclastic differentiation and activation [177]. The enhanced osteoclast 
activity in RA is due to a multiplicity of reasons that range from cellular effects to pro-inflammatory 
cytokines to autoantibodies [176]. MCSF, RANKL, TNF, IL-1, and IL-17 are pro-inflammatory 
cytokines that may play dominant roles in the pathogenesis of rheumatoid arthritis by participating 
in osteoclast differentiation [124].  
There is evidence that joint damage and bone erosion in RA patients begins at a very early stage of 
the disease, progressing throughout its course. In fact, the first bone erosions perceived by 
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radiographic studies appear to occur during the first 2 years of the disease [178]. Both the 
development of erosions and the degree of radiological progression can be predicted by the 
rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) levels at the first 
presentation in RA patients. This indicates that RF and anti-CCP positive patients present a higher 
risk for developing bone erosions with increased severity, within the first years of disease onset 
[179].  
Many factors contribute to control the activity of osteoclasts within normal bone tissue and normal 
bone remodeling metabolism [148]. The complex crosstalk between the osteoclasts and 
neighboring cells (such as osteoblasts, osteocytes, and hematopoietic cells), along with the 
biochemical microenvironment, is crucial to normal osteoclastogenesis. There is evidence that 
certain immune complexes found in the joint of RA patients can induce macrophage activation and 
participate in synovial inflammation, possibly playing a role in the control of osteoclastogenesis 
[180,181]. Immune complexes containing anticitrullinated peptide antibodies (ACPA) may have a 
greater ability to stimulate osteoclastogenesis, consequently inducing an increased bone loss in RA 
patients [182,183]. Recent data suggest that besides being activated by immune cells, osteoclasts 
can play an active role in inducing or perpetuating the autoimmune feedback loops and 
inflammatory response in RA. They are capable of antigen presentation, which results in T cell 
activation [184]. 
 
 
 
5. Long non-coding RNAs (lncRNAs) 
Due to the central dogma of “DNA → RNA → protein”, the research of the last few decades have 
mainly been focused on the role of protein-coding genes in the pathogenesis of the disease. As 
proteins are counted as key players of cellular functions, RNA is regarded to be a mere intermediary 
between genes and proteins [185]. However, in recent years this paradigm has been changed. Due 
to the developing of new technologies, including genome and transcriptome sequencing, evidence 
arises suggesting that the noncoding portions of the genome may regulate the complexity of an 
organism [186]. In fact, the so-called “junk DNA”, that comprises the noncoding portions of the 
genome, might significantly contribute to the higher eukaryotic sophistication, regulating gene 
expression, structural and functional mechanisms in cells and disease pathogenesis [187]. This 
concept resulted in the establishment of the Encyclopedia of DNA Elements (ENCODE) Consortium 
in 2003, that aimed to identify all the functional elements in the human genome [188,189]. The 
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ENCODE project reported that about 90% of the genome is transcribed as nonprotein-coding RNAs 
(ncRNAs), indicating that this might not be junk hereafter [190–192]. 
These transcripts that do not hold any protein-coding capacity are called non-coding RNA (ncRNA). 
Depending on their length, these can be classified as small non-coding RNAs (sncRNAs) and long 
non-coding RNAs (lncRNAs). Small non-coding RNAs are shorter than 200 nucleotides and consist 
mainly of microRNAs (miRNA) and small nuclear RNAs (snRNA) [193]. Long non-coding RNAs 
(lncRNAs) are RNAs longer than 200 nucleotides, that can be subclassified based on their 
intersection with protein-coding genes as intergenic or genic lncRNAs [194]. Intergenic lncRNAs do 
not intersect with any protein-coding loci. Genic lncRNAs comprise three biotypes: exonic lncRNA 
(at least one of its exons intersects a protein-coding exon by at least 1 bp), intronic lncRNAs 
(contained completely within a sense or antisense protein-coding introns) and overlapping lncRNAs 
(contain a sense or antisense coding gene within an intron) [194]. According to GENCODE v7, the 
lncRNAs are the most common however least well-understood RNA species [194]. 
The number of lncRNAs is larger than the number of protein-coding RNAs, but they are generally 
expressed at lower levels compared to protein-coding genes, and appear to be tissue or cell-type 
specific [193–195]. These RNAs can modulate gene expression through multiple mechanisms, such 
as epigenetics, miRNA sponging, alternative splicing, and transcriptional and translational 
regulation [193,196–199]. Additionally, lncRNAs appear to participate in several biological 
processes, such as cell proliferation, morphogenesis, pluripotency, development, neuronal 
processes, and gametogenesis [200]. Furthermore, the dysregulation of lncRNAs has increasingly 
been linked to many human diseases, especially in cancers [185,186,190,191,196,201,202]. 
 
 
5.1 lncRNAs in rheumatoid arthritis 
Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression in the 
immune system and inflammatory responses [203,204]. These RNAs can regulate both the innate 
and adaptative immune responses [205–207]. Recent reports demonstrated that lncRNAs play a 
key role in the pathogenesis of a variety of autoimmune diseases, such as multiple sclerosis, 
systemic lupus erythematosus, type I diabetes and RA [208–211]. However, current knowledge of 
RA-related lncRNAs remains limited. The long non-coding RNA expression profile in rheumatoid 
arthritis patients has been mainly studied in fibroblast-like synoviocytes (FLSs) and peripheral blood 
mononuclear cells (PBMCs) [212–214].  
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An interesting analysis of the lncRNA–miRNA–mRNA functional network by Jiang et al., revealed 
functional lncRNAs in rheumatoid arthritis, indicating that these might play important roles in the 
development of RA [215]. Although the biological functions and molecular mechanisms of these 
lncRNAs are not yet elucidated, some appear to be highly related to RA. The authors suggest that 
specific lncRNAs are associated with the development of RA, and highlight three lncRNAs (S5645.1, 
XR_006437.1, J01878) that could be used as potential diagnostic biomarkers and therapeutic 
targets [215]. A comprehensive analysis of lncRNA and mRNA expression profiles in rheumatoid 
arthritis patients was performed by Luo et al., using human lncRNA microarray to analyze the 
PBMCs of RA patients and healthy controls [212].  A total of 5,045 lncRNA (2,410 upregulated and 
2,635 downregulated) were differentially expressed in patients with RA [212]. 
The expression of lncRNAs and mRNAs in the PBMCs of RA patients and their role in RA 
pathogenesis was described by Yuan et al. [213]. Song et al., reported several lncRNAs with altered 
expression in PBMCs of RA patients, including Sox2OT, H19, Meg3, GAS5, NEAT1, Meg9, DANCR and 
HOTAIR [223]. Yang et al., reported that the lncRNA NTT is expressed in human 
monocytes/macrophages and its expression is highly upregulated (around 100- to 1000-fold of 
normal control) in the PBMCs of early-untreated RA patients, showing a positive correlation with 
the initial disease activity score (DAS28) [216].  
Zhang et al., described 62 upregulated lncRNAs and 73 downregulated lncRNAs in fibroblast-like 
synoviocytes from RA patients [214]. ZFAS1 is a recently described lncRNA known to be upregulated 
and to promote cell migration and invasion is several cancers [217–219]. Ye and its co-authors 
hypothesize that given these effects on cancer cells, ZFAS1 could also influence the migratory and 
invasive phenotypes in FLSs of rheumatoid arthritis patients [220]. In fact, they found that ZFAS1 
expression is increased in synovial tissue and FLS from RA patients, and showed that silencing ZFAS1 
suppressed FLS migration and invasion, while overexpression of ZFAS1 showed the opposite effect 
[220].  
Li et al., recently described a marked down-regulation of the lncRNA GAS5 in FLS of RA patients, 
suggesting that GAS5 down-regulation could be a pathological feature of RA [221]. GAS5 was also 
found to be down-regulated in both B-cells and CD4 T-cells of RA patients, although its mechanism 
and role in the pathophysiology of RA has not been yet elucidated [222]. One possibility is that GAS5 
might participate in the regulation immune functions and pathogenesis of autoimmune and 
inflammatory diseases by modulating the glucocorticoid receptor (GR) transcriptional activity 
through its decoy RNA glucocorticoid response element (GRE) [222]. It was also reported that GAS5 
expression is upregulated in PBMCs of RA patients [223]. 
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NEAT1 is a lncRNA known to be an important regulator of the inflammatory process and highly 
expressed in monocytes [224]. Although there is scarce evidence of its expression in patients and 
role in RA pathology, it represents a putative target of interest. It is upregulated in the blood 
exosomes of RA patients, with a pathological relevance based in a view of delivering molecules at 
distances beyond that of direct cell-to-cell contact [223]. It is also upregulated in PBMCs of RA 
patients [223]. 
Recently, MEG3 was also proposed as an important lncRNA in RA pathogenesis. A research work by 
Liu et al. reported that MEG3 is significantly reduced in synovial tissue and FLSs of an RA animal 
model (complete Freundʼs adjuvant [CFA]‐induced rats) [225]. It presents a methylation-dependent 
mechanism and regulates arthritis in this animal model by targeting the NOD-like receptor family 
CARD domain containing 5 (NLRC5) and regulating its expression. This, in turn, affects the 
proliferation of FLSs because NLRC5 promotes FLSs proliferation in RA. The enforced expression of 
MEG3 decreased NLRC5 expression, leading to a decreased in FLSs numbers. Loss of MEG3 in RA is 
because of the hypermethylation of its promoter [225]. 
HOTAIR is a lncRNA that has been gaining attention for its possible role in RA pathogenesis. A study 
by Song et al., reported a notably high expression level of HOTAIR in both PBMCs and serum 
exosomes of RA patients, ultimately potentiating the migration of active macrophages [223]. It can 
function as an attractive cue for activated macrophage as well as a stimulatory cue for MMP 
production and activation from synovial fibroblasts. In contrast, the authors described a markedly 
lower level of expression of HOTAIR in in vitro differentiated osteoclasts and also in RA patients 
synoviocytes (isolated from biopsies of synovial membrane or samples of synovial fluid) [223]. 
Consistently, the enforced expression of HOTAIR in both osteoclasts and synoviocytes led to 
significantly decreased levels of MMP-2 and MMP-13 [223].  
 
 
6. Aim of the study 
Bone erosions in RA patients result from imbalanced bone metabolism due to excessive 
osteoclastogenesis and osteoclastic activity. Long non-coding RNAs (lncRNAs) have been implicated 
in osteoclastogenesis and RA pathophysiology. However, no study has yet examined lncRNAs 
expression in monocytes and osteoclasts of RA patients. This work aims to address this question by 
analyzing in monocytes and osteoclasts of RA patients and of healthy controls the expression of a 
panel of 8 lncRNAs (GAS5, NEAT1, Meg3, DANCR, HOTAIR, Meg9, H19, and Sox2OT), that have been 
shown to be altered during mouse osteoclastogenesis and/or altered in several cellular types in RA. 
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PATIENTS AND METHODS 
 
1. Patients and healthy controls 
This study was approved by the ethics committee of Hospital de Santa Maria and all participants 
signed informed consent prior to enrollment. Patients with RA fulfilling the 2012 American College 
of Rheumatology/European League Against Rheumatism criteria [60] were recruited from the 
Rheumatology Department, Hospital de Santa Maria, Lisbon Academic Medical Centre, Portugal. 
The remaining inclusion criteria for the study groups are summarized in Table 1. 
Heparinized blood was collected from each participant and whole blood samples were taken for 
isolation of peripheral blood mononuclear cells (PBMCs). Samples were stored at the Biobanco-
IMM, Lisbon Academic Medical Center, Lisbon, Portugal. Age and sex-matched donors were used 
as healthy controls.  
 
Table 1 - Summary of the inclusion criteria for the study groups. 
Group name Inclusion criteria 
Early-untreated arthritis < 1-year disease onset, untreated 
Established rheumatoid arthritis DAS28 > 3.2, MTX, PDN < 10mg/day 
Healthy controls Age and sex matched 
DAS – disease activity score; MTX – methotrexate; PDN - prednisolone   
 
 
2. Peripheral blood mononuclear cells (PBMCs) isolation 
PBMCs were isolated by density gradient centrifugation using Lymphocyte Separation Medium 
solution (1.077 g/mL; Lonza, USA) as represented in Figure 3. 60 mL of blood was collected from 
each patient and healthy donor. Sodium heparin was used as an anticoagulant. Heparinized blood 
samples were diluted at 1:2 volume in a 50 mL centrifuge tube with sterile 1x Phosphate Buffer 
Saline (PBS) (15 mL of blood to 30 mL of PBS). Diluted blood was carefully added to Lymphocyte 
Separation Medium solution at 1:2 volume in a 50 mL centrifuge tube (15 mL of the solution to 30 
mL of diluted blood), creating a defined layer. Samples were centrifugated for 30 min at 2000 rpm, 
with no brake and no acceleration, at 20 °C. This step created four distinct layers (from top to 
bottom): top layer containing the plasma, the layer of interest containing the PBMCs, a third layer 
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containing the Lymphocyte Separation Medium solution and a bottom layer with red blood cells 
(RBCs). The layer containing PBMCs was then carefully removed from each tube and washed two 
times with PBS, as follows. No more than 20 mL of PBMCs were placed in a new 50 mL centrifuge 
tube, and PBS was added up to a total volume of 50 mL. Samples were centrifuged for 15 min at 
2000 rpm, at 20 °C. The supernatant was discarded, and the remaining pellet resuspended in 2 mL 
of PBS. All the resuspended pellets were collected to one of the tubes, and PBS was added up to a 
total volume of 50 mL. Samples were centrifuged for 10 min at 2000 rpm, at 20 °C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The supernatant was discarded, and the pellet was resuspended in 10 mL of PBS.  Viable cells were 
counted on a hemocytometer, using 0.4% Trypan Blue solution (Sigma® Life Science, UK). Samples 
were again centrifugated for 10 min at 2000 rpm, at 20°C. The supernatant was discarded, and the 
cell pellet was then resuspended in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, USA) 
supplemented with 1% 5000 U Penicillin/Streptomycin solution (Invitrogen, USA) and 10% Fetal 
Bovine Serum (FBS; Invitrogen, USA), with the volume necessary to obtain the desired cell density. 
 
 
3. Cell culture and osteoclastogenesis 
The obtained PMBCs were seeded on plastic cell culture dishes (60.1 cm2; Ø 87 mm; TPP®, 
Switzerland) at a density of 3,0 x 106 cells/mL in DMEM supplemented with 1% 5000 U 
Figure 3 - PBMCs isolation with Lymphocyte Separation Medium (https://bioscience.lonza.com) 
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Penicillin/Streptomycin solution and 10% Fetal Bovine Serum (FBS). For functional assays cells were 
seeded on 12-well plastic cell culture dishes (3.8 cm2; Ø 22.1 mm; Costar® Corning®, USA), on square 
coverslips (10 x 10 mm), at the same cell density. PBMCs were incubated in a humidified 
atmosphere at 37°C, 5% CO2 and left overnight for monocytes to adhere to the plates. On the 
following day (day 1 of culture) selected plates with adherent monocytes were used for RNA 
extraction. For the remaining plates, including the 12-well plates, the in vitro 21-day protocol for 
osteoclastogenesis was performed as follows. At day 1 medium was changed to DMEM 
supplemented with M-CSF 25 ng/mL (Peprotech, USA) to initiate the differentiation process. Three 
days later (day 4 of culture), medium was changed to DMEM supplemented with M-CSF, sRANKL 
(50 ng/mL; Peprotech, USA), dexamethasone (10 nM; Sigma Aldrich, USA) and TGF-β (2.5 ng/mL; 
Peprotech, USA) to fully differentiate the osteoclast precursor cells into mature osteoclasts. The 
culture medium was then changed every 3 days using the same formulation until day 21 of culture. 
At this point, cultured mature osteoclasts were used for RNA extraction and TRAP staining.  
 
 
4. Osteoclasts functional assay (TRAP staining) 
Tartrate-resistant acid phosphatase (TRAP) staining of osteoclasts was performed at day 21 of 
culture using the Acid Phosphate Leukocyte Kit (TRAP; Sigma-Aldrich, USA) for the cytologic 
demonstration of the expression of acid phosphatase in mature osteoclasts. Osteoclastogenesis 
was performed by a 21-day differentiation protocol of adherent monocytes in square coverslips (10 
mm2). The fixative solution was prepared by combining 25 mL of citrate solution, 65 mL of acetone 
and 8 mL of 37% formaldehyde, placed in a glass bottle and capped tightly. 100 mL of distilled water 
was prewarmed at 37°C and the fixative solution was brought to room temperature (18–26°C).  Cells 
were fixed by immersion in fixative solution for 30 seconds and then rinsed thoroughly in deionized 
water, never allowing coverslips to dry. In a 1 mL microtube were added 0,5 mL Fast Garnet GBC 
Base Solution and 0.5 mL Sodium Nitrite Solution, then mixed by gentle inversion for 30 seconds 
and let stand for 2 minutes. Next, a solution containing: 45 mL of deionized water prewarmed to 
37°C, 1 mL of Diazotized Fast Garnet GBC Solution from the previous step, 0,5 mL of Naphthol AS-
Bl Phosphate Solution, 2 mL of acetate solution and 1 mL of tartare solution was prepared and 
warmed to 37 °C. Coverslips were immersed in this solution and incubated for 30 min at 37°C, 
protected from light. After 30 min, coverslips were rinsed thoroughly in deionized water, then 
counterstained for 1 min in Hematoxylin Solution, Gill No. 3. Next, coverslips were rinsed for several 
minutes in alkaline tap water to blue nuclei and left to air dry. Finally, coverslipping was performed 
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with Quick-D mounting medium (Klinipath, Nederland), and slides were evaluated microscopically 
using an optical microscope (Leica DM2500; Leica Microsystems, Germany), for counting mature 
osteoclasts (TRAP+ and three or more nuclei). 
 
 
5. Total RNA extraction 
Total RNA was extracted from monocytes and osteoclasts with the RNeasy® Mini Kit (Qiagen, USA), 
using the Purification of Total RNA from Animal Cells using Spin Technology Protocol. Culture 
medium was aspirated, and cells were washed two times with PBS. At least 5 mL of PBS was added 
to each culture dish, cells were harvested, and the total volume of resuspended cells was 
transferred into a 15 mL or 50 mL centrifuge tube, depending on the volume obtained. Samples 
were centrifugated for 5 min at 2000 rpm, at 4°C. The supernatant was discarded, the pellet was 
resuspended in 1 mL of PBS and the suspension was transferred into a 1.5 mL microtube. Viable 
cells were counted on a hemocytometer, using Trypan Blue solution (Sigma® Life Science, UK). 
Samples were centrifuged for 5 min at 12800 rpm, at 4°C. The supernatant was discarded, and the 
cell pellet was loosened thoroughly by flicking the tube. Next, depending on the total number of 
cells, either 350 µL (< 5 x 106 cells) or 600 µL (5 x 106 – 1 x 107 cells) of Buffer RLT was added for 
lysing the pelleted cells. The lysate was homogenized by pipetting and vortexing. The protocol was 
usually interrupted at this step by snap freezing the samples with liquid nitrogen, and storing them 
at -80°C. To proceed with total RNA extraction, 1 volume of 70% ethanol was added to the 
homogenized lysate and mixed well by pipetting.  Up to 700 µL of the sample was transferred to an 
RNeasy spin column placed in a 2 mL collection tube. If the sample volume exceeded 700 µL, 
successive aliquots were centrifuged in the same RNeasy spin column, and the flow-through 
discarded after each centrifugation. All the following centrifugation steps were performed at 20-
25°C. Samples were centrifuged for 15 s at 8000 g and the flow-through was discarded. Next, on-
column DNase digestion with the RNase-Free DNase Set (Qiagen, USA) was performed. 350 µL of 
Buffer RW1 was added to the RNeasy spin column, followed by a centrifugation step for 15 s at 
8000 g, to wash the spin column membrane. The flow-through was discarded. 10 µL of DNase I 
stock solution was added to 70 µL of Buffer RDD, mixed by gently inverting the tube, and 
centrifuged briefly to collect residual liquid from the sides of the tube. The DNase I incubation mix 
(80 µL) was added directly to the RNeasy spin column membrane, and tubes were placed on the 
benchtop (20–30°C) for 15 min. Next, 350 µL of Buffer RW1 was added to the RNeasy spin column. 
Samples were centrifuged for 15 s at 8000 g, and the flow-through was discarded. To proceed with 
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extraction, 500 µL of Buffer RPE was added to the RNeasy spin column. Samples were centrifuged 
for 15 s at 8000 g, to wash the spin column membrane. The flow-through was discarded. Another 
500 µL of Buffer RPE was added to the RNeasy spin column. Samples were centrifuged for 2 min at 
8000 g, to wash the spin column membrane. The RNeasy spin column was then placed in a new 2 
ml collection tube, and the old collection tube was discarded with the flow-through. Samples were 
centrifuged at full speed for 1 min. This step allows the elimination of any possible carryover of 
Buffer RPE, or any residual flow-through remaining on the outside of the RNeasy spin column after 
the previous step. Then, the RNeasy spin column was placed in a new 1.5 ml collection tube, and 
30 µL of RNase-free water was added directly to the spin column membrane. Samples were 
centrifuged for 1 min at 8000 g, to elute the RNA. The total RNA concentration and purity were 
quantified using Nanodrop 1000 (Thermo Scientific, USA). Samples were stored at -80°C. 
 
 
6. Complementary DNA (cDNA) synthesis  
Complementary (c)DNA was synthesized for each RNA sample at a concentration of 50 ng/μL using 
the NZY First-Strand cDNA Synthesis Kit, separate oligos (NZYTech, Portugal) as follows. The 
reaction was performed using a Tpersonal Thermal Cycler (Biometra®, Germany). The annealing 
reaction was performed on ice, by adding the following components into a sterile, nuclease-free 
microcentrifuge tube: 1 µg of RNA, 1 µL of random hexamer mix (50 ng/µL), 1 µL of 10× Annealing 
Buffer, and up to 8 µL of Nuclease-free water. Next, the samples were mixed gently and incubated 
at 65°C for 5 min. After incubation, samples were placed on ice for at least 1 min and then 
centrifuged briefly. On the ice, the reverse-transcription step was performed by adding 10 µL of 
NZYRT 2× Master Mix, no oligos, and 2 µL of NZYRT Enzyme Mix to the tube. Samples were mixed 
gently and centrifuged briefly, prior to incubation at 25 °C for 10 min and then at 50 °C for 30 min. 
The reaction was inactivated by heating at 85 °C for 5 min and then chilling the tubes on ice. Finally, 
1 µL of NZY RNase H was added to each tube and samples were incubated at 37°C for 20 min. The 
cDNA product was stored at -20 °C until required. 
 
 
7. Real-time quantitative PCR (RT-qPCR) 
Each cDNA template was amplified in triplicate using PowerUp™ SYBR™ Green Master Mix (Applied 
Biosystems, USA). RT-qPCR was carried out using a ViiA 7 Real-Time PCR System (Applied 
Biosystems, USA). For this work, a panel of 8 lncRNAs was analyzed: GAS5, NEAT1, Meg3, DANCR, 
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HOTAIR, Meg9, H19, and Sox2OT (see Table 2 for primers). For the calibration curve, cDNA was 
diluted in 5 different concentrations. Ten μL reactions were set up in 384-well plates with 10 μM of 
each primer (diluted at 1:10) and 5 μL of PowerUp™ SYBR™ Green Master Mix (Applied Biosystems, 
USA). For RT-qPCR, 1 μL of the 20 μL reverse transcription reaction mixture was used (final cDNA 
concentration = 10 ng/μL). Cycling conditions were as follows: UDG activation (50°C for 2 min), 
Dual-Lock™ DNA polymerase (95°C for 2 min), denaturation (95°C for 15 s), annealing/extension 
(60°C for 1 min), repeated 40 times (40 cycles). Cycling mode was followed by a melt curve stage as 
follows: step 1 with ramp rate of 1.6°C/second (95°C for 15s), step 2 with ramp rate of 1.6°C/second 
(60°C for 1 min), dissociation at step 3 with ramp rate of 0.15°C/second (95°C for 15s). All targets 
were subject to melt curve analysis to test if any unspecific PCR products were generated. 
Amplification curves were analyzed for relative quantification using QuantStudio™ Real-Time PCR 
Software v1.3 analysis software (Applied Biosystems, USA). Target expression was normalized to 
the expression of the housekeeping gene (GAPDH) according to the comparative CT method and 
presented as the geometric mean of relative fold expression (2-ΔΔCT). 
 
 
Table 2 - Primers used for lncRNAs expression analysis. 
lncRNA Primer sequence 
GAPDH 
(housekeeping gene) 
Fw 5’– GTCGTGGAGTCCACTGGCGTC – 3’ 
Rev 5’ – TCATGAGTCCTTCCACGATAC – 3’ 
GAS5 
Fw 5’– AGAAATGCAGGCAGACCTGT – 3’ 
Rev 5’ – GCACTCTAGCTTGGGTGAGG – 3’ 
NEAT1 
Fw 5’ – GTGGCTGTTGGAGTCGGTAT – 3’ 
Rev 5’ – ATTCACTCCCCACCCTCTCT – 3’ 
Meg3 
Fw 5’ – CAGCCAAGCTTCTTGAAAGG – 3’ 
Rev 5’ – TTCCACGGAGTAGAGCGAGT – 3’ 
DANCR 
Fw 5’ – GCCACTATGTAGCGGGTTTC – 3’ 
Rev 5’ – ACCTGCGCTAAGAACTGAGG – 3’ 
HOTAIR 
Fw 5’ – GTGTAGACCCAGCCCAATTTA – 3’ 
Rev 5’ – GGCTGGACCTTTGCTTCTAT – 3’ 
Meg9 
Fw 5’ – GGCATCCCTGTACCTAGCAC – 3’ 
Rev 5’ – AGAGACAAGGCCAACAAGCA – 3’ 
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H19 
Fw 5’ – TTCAAAGCCTCCACGACTCT – 3’ 
Rev 5’ – CTGAGACTCAAGGCCGTCTC – 3’ 
Sox2OT 
Fw 5’ – GCTCGTGGCTTAGGAGATTG – 3’ 
Rev 5’ – CTGGCAAAGCATGAGGAACT – 3’ 
 
 
 
8. Statistical analysis 
GraphPad Prism 7.0 (GraphPad Software, USA) was used to analyze the data. The nonparametric 
Mann-Whitney test was used to compare the lncRNAs relative expression levels between two 
groups. Spearman’s correlations were performed between the expression levels of the lncRNAs and 
clinical variables (ESR, CRP, tender and swollen joint count, and DAS28).  p-values (two-tailed) <0.05 
were considered statistically significant. 
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RESULTS 
 
1. Patients and healthy controls 
Twenty-seven subjects were initially recruited, including 8 established rheumatoid arthritis 
patients, 5 early arthritis patients and 14 age and gender-matched healthy donors. However, our 
study was only completed for 17 subjects (7 established RA patients, 3 early arthritis patients, and 
7 healthy controls). As for the early arthritis patients, 2 have been diagnosed with RA and 1 still has 
a reserved diagnosis of rheumatic polymyalgia/seronegative RA. The clinical and demographic 
characteristics of the patients and healthy donors included in this study are described in Table 3. 
Early arthritis patients were all untreated. All established RA patients were on a low corticosteroid 
dose (prednisolone <10mg/day) and synthetic DMARDs monotherapy (4 on methotrexate and 3 
with methotrexate plus hydroxychloroquine). None of the patients were on biological therapy. 
 
Table 3 - Summary of the patients and healthy controls' characteristics. 
 
Healthy controls 
Early arthritis 
patients 
Established RA 
patients 
Sample size 7 3 7 
Age (years) 50 [48-62] 66 [64-78] 56 [43-65] 
Females % 57% 67% 86% 
Symptoms 
duration (years) 
NA 0,4 [0,25-1] 4 [2-7] 
Rheumatoid factor 
(% positive) 
NA 67 100 
ACPA (% positive) NA 67 100 
ESR (mm/h) NA 86 [52-88] 29 [8-55] 
CRP (mg/dl) NA 1,2 [0,5-2,13] 0,56 [0,06-2,29] 
DAS28 NA 5,34 [3,15-7,06] 3,76 [2,9-4,91] 
Treatment NA none sDMARDS 
Data is represented as median [Interquartile range] unless stated otherwise; ACPA – anti-citrullinated protein 
antibodies; ESR – erythrocyte sedimentation rate; CRP – C-reactive protein; DAS – disease activity score; 
DMARDs – disease modifying antirheumatic drugs; RA – rheumatoid arthritis; NA – not applicable. 
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2. Cell culture, osteoclastogenesis, and total RNA extraction 
The intended course of action of the study was to analyze both monocytes and osteoclasts from all 
study groups. However, due to technical limitations, such as lack of adequate starting number of 
cells (PBMCs) to isolate both monocytes and osteoclasts, it was not possible to achieve this goal. As 
so, the work became more focused on the collection and study of monocytes. In addition, the 
concentration of the obtained RNA was not high enough for reverse transcription reaction in some 
samples. A summary of the obtained RNA samples, suitable for cDNA synthesis and further analysis, 
from both monocytes and osteoclasts of all study groups, is described in Table 4. 
 
Table 4 - Summary of the obtained RNA samples from both monocytes and osteoclasts of all study groups. 
 
Healthy controls 
Early arthritis 
patients 
Established RA 
patients 
Monocytes n = 5 n = 2 n = 7 
Osteoclasts n = 4 n = 2 n = 0 
 
 
 
3. Osteoclasts functional assay (TRAP staining) 
Osteoclasts (OCs) were stained for tartrate-resistant acid phosphatase (TRAP) at day 21 of culture. 
TRAP staining was performed to demonstrate the expression of TRAP in mature osteoclasts and 
thus to serve as a biochemical marker for active osteoclasts [226]. Acid phosphatase activity 
appears as purplish to dark red granules in the cytoplasm of mature osteoclasts Figure 4A. In this 
assay TRAP-positive cells containing three or more nuclei were counted. As shown in Figure 4B, in 
vitro osteoclastogenesis produced a substantially higher number of osteoclasts in early arthritis 
patients (1134,5±19,5 OCs/mm2 [mean±SD]), when compared to healthy controls (279,25±140,30 
OCs/mm2 [mean±SD]). As the same starting number of cells was used (3,0 x 106 cells/mL) in all 
samples, these results suggest that peripheral monocytes of early arthritis patients are more prone 
to osteoclastogenesis. 
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Figure 4 - TRAP staining of in vitro differentiated osteoclasts. A: representative image of OCs of healthy 
controls (top) and early arthritis patients (bottom) (10× magnification) at culture day 21, stained for TRAP. 
Black arrows – osteoclasts. B: OC number were increased in early arthritis patients (n=2), when compared to 
healthy controls (n=4). Each dot represents a sample. Data presented as median with interquartile range. 
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4. lncRNAs expression analysis by RT-qPCR 
A panel of 8 lncRNAs was analyzed (GAS5, NEAT1, Meg3, DANCR, HOTAIR, Meg9, H19, and Sox2OT) 
in both monocytes and osteoclasts from healthy controls (n=5 and n=4, respectively), early arthritis 
patients (n=2 and n=2, respectively) and in monocytes from established rheumatoid arthritis 
patients (n=7). From these, measurable and reproducible expression was only observed for 3 
lncRNAs (GAS5, NEAT1, and DANCR) by RT-qPCR in all samples of both monocytes and osteoclasts, 
of all the study groups. As so, the results herein presented refer only to the expression levels of 
GAS5, NEAT1, and DANCR. 
As shown in Figure 5, NEAT1 presents an increased expression in monocytes of both early arthritis 
patients and established RA patients, when compared to monocytes of healthy controls. GAS5 
appears to have an increased expression in monocytes of established RA patients, and a decreased 
expression in monocytes of early arthritis patients, when compared with those of healthy controls. 
DANCR shows a slight decrease in expression in monocytes of established RA patients and no 
differences in early arthritis patients when compared to healthy controls. However, no statistically 
significant differences were found between monocytes of healthy controls and established RA 
patients, in either of lncRNAs.  
The expression of these lncRNAs was also analyzed in osteoclasts of early arthritis patients and 
healthy controls Figure 6. NEAT1 presents an increased expression in osteoclasts of early arthritis 
patients when compared to those of healthy controls. Regarding GAS5 and DANCR, they both show 
a slightly decreased expression in osteoclasts of early arthritis patients, when compared to those 
of healthy controls.  
A comparison of the relative expression of these lncRNAs between monocytes and osteoclasts was 
performed for both healthy controls and early arthritis patients, and it is presented in Figure 7 and 
Figure 8, respectively. In healthy controls, osteoclasts have an increased expression of both NEAT1, 
GAS5, and DANCR, when compared to monocytes. However, no statistically significant differences 
were found between monocytes and osteoclasts of healthy controls, in either of lncRNAs.  
Regarding early arthritis patients, the same tendency of increased expression in osteoclasts is 
observed for GAS5 and DANCR. In contrast, NEAT1 expression is decreased is osteoclasts of early 
arthritis patients, when compared to monocytes. 
For the remaining lncRNAs, no measurable expression was detected for all samples in all groups 
(data not shown). As primer optimization was performed in PMBC RNA samples, we can conclude 
that both monocytes and osteoclasts do not express these lncRNAs in all the experimental groups 
tested.  
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On the following table (Table 5) we present the values for relative expression of NEAT1, GAS5, and 
DANCR, along with median and interquartile range. The expression was normalized for the 
housekeeping gene (GAPDH) expression values. Some values were excluded (*) for the analysis, 
based on high discrepancy relative to the remaining values of the group. 
 
Table 5 - Relative expression values for NEAT1, GAS5, and DANCR. 
 
Monocytes 
HC 
Monocytes 
RA 
Monocytes  
EA 
Osteoclasts 
HC 
Osteoclasts 
EA 
NEAT1 
4,469* 
0,46 
0,571 
0,824 
1,035 
1,306 
1,238 
1,002 
0,804 
1,238 
0,034* 
1,27 
2,533 
2,128 
2,358 
0,434 
0,976 
1,299 
1,558 
Median 
[IQ range] 
0,6975 
[0,46-1,035] 
1,238 
[0,804-1,306] 
2,3305 
[2,533-2,128] 
0,976 
[0,434-0,976] 
1,4285 
[1,299-1,558] 
GAS5 
4,441* 
0,26 
0,835 
0,52 
1,995 
0,66 
0,288 
2,852 
1,319 
1,009 
0,259 
5,558* 
0,331 
0,585 
1,494 
0,691 
0,968 
0,75 
0,849 
Median 
[IQ range] 
0,6775 
[0,26-1,995] 
0,8345 
[0,259-2,852] 
0,458 
[0,331-0,585] 
0,968 
[1,494-0,691] 
0,7995 
[0,75-0,849] 
DANCR 
3,728* 
0,493 
0,911 
0,728 
0,82 
0,719 
0,652 
1,31 
0,555 
0,661 
0,226 
3,316* 
0,797 
0,876 
0,75 
1,198 
1,113 
0,892 
1,037 
Median 
[IQ range] 
0,774 
[0,493-0,911] 
0,6565 
[0,226-1,31] 
0,8365 
[0,797-0,876] 
1,113 
[0,75-1,198] 
0,9645 
[0,892-1,037] 
*excluded values – based on discrepancy within the group  
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Figure 5 - Relative expression of NEAT1, GAS5 and DANCR in monocytes from healthy controls (n=4), 
early arthritis patients (n=2) and established rheumatoid arthritis patients (n=6). Data was normalized 
for housekeeping gene (GADPH) expression levels. No statistically significant differences were found 
between healthy controls and established RA patients. Each dot represents a sample. Data presented as 
median with interquartile range. RA – rheumatoid arthritis; MO – monocytes. 
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Figure 6 - Relative expression of NEAT1, GAS5 and DANCR in osteoclasts from healthy controls (n=3), and 
early arthritis patients (n=2). Data was normalized for housekeeping gene (GADPH) expression levels. No 
statistical analysis was performed due to insufficient number of samples. Each dot represents a sample. Data 
presented as median with interquartile range. OC – osteoclasts. 
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Figure 7 - Relative expression of NEAT1, GAS5 and DANCR in monocytes (n=4) and osteoclasts (n=3) from 
healthy controls. Data was normalized for housekeeping gene (GADPH) expression levels. No statistically 
significant differences were found between monocytes and osteoclasts of healthy controls. Each dot 
represents a sample. Data presented as median with interquartile range. HC – healthy control; MO – 
monocytes; OC – osteoclasts. 
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Figure 8 - Relative expression of NEAT1, GAS5 and DANCR in monocytes (n=2) and osteoclasts (n=2) from 
early arthritis patients. Data was normalized for housekeeping gene (GADPH) expression levels. No statistical 
analysis was performed due to insufficient number of samples. Each dot represents a sample. Data 
presented as median with interquartile range. EA – early arthritis; MO – monocytes; OC – osteoclasts. 
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5. Correlation of lncRNAs expression and clinical variables 
A Spearman correlation analysis of the expression levels of NEAT1, GAS5 and DANCR in monocytes 
of established RA patients was performed for the following clinical variables: erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), number of tender joints, number of swollen 
joints and disease activity score (DAS28). The results are summarized in Table 6. 
In established RA patients, GAS5 expression in monocytes was significantly negatively correlated 
with the number of tender joints (r= -0.9063, p= 0.0095). Data are represented in Figure 9 along 
with the linear regression analysis obtained for this correlation. 
 
Table 6 - Spearman correlation analysis of lncRNAs expression and clinical variables of RA patients. 
 NEAT1 GAS5 DANCR 
 r p value r p value r p value 
ESR -0,1081 0,8206 0,2143 0,6615 0,1786 0,7131 
CPR 0,02727 0,9599 0,4505 0,3111 0,5586 0,2056 
Tender joints -0,169 0,7143 -0,9063 0,0095 ** -0,5714 0,2000 
Swollen joints -0,01888 0,9952 -0,2433 0,5952 0,05614 0,9238 
DAS28 -0,2342 0,6198 -0,1786 0,7131 -0,03571 0,9635 
** significance considered for p value < 0,05 
   
 
 
 
 
 
 
 
Figure 9 - Correlation analysis between GAS5 expression and the number of tender joints in RA patients. Line 
represents linear regression obtained for these variables: Y = -0,5045*X + 2,004; R2 = 0,3319. 
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DISCUSSION 
 
All in all, rheumatoid arthritis can be characterized by synovial inflammation and hyperplasia 
(“swelling”) in joints, autoantibody production, cartilage and bone destruction, and systemic 
manifestations [34]. Bone erosion is a crucial hallmark of RA pathophysiology and is associated with 
disease severity [51]. There is evidence that bone erosions start to occur within the first year of 
disease onset, representing one of the first and most important features of RA pathogenesis 
[178,179]. These erosions in RA patients result from an imbalanced bone metabolism due, in part, 
to excessive osteoclastogenesis and osteoclastic activity, that leads to increased bone resorption 
by osteoclasts [50–52]. Besides being responsible for bone resorption, osteoclasts are key players 
in the complex cross-talk between bone and immune cells, that leads to the perpetuation of the 
inflammatory environment in joints of RA patients [53–55].  
Once established, bone erosions rarely repair. Current biological and synthetic DMARDs 
therapeutic can control inflammation in RA, achieving clinical remission or low disease activity, halt 
the erosive process and lead to partial repair of bone erosions. However, up until now, these drugs 
cannot induce full repair and regression of the erosions [51,175]. 
It is then imperative to find new, more effective, and targeted therapeutic approaches to 
osteoclasts and osteoclastogenesis, to prevent bone erosion in RA patients and control the 
inflammatory cascades. For this, we must first understand the pathophysiological mechanisms 
underlying the excessive osteoclastogenesis and osteoclastic activity present in RA. In this regard, 
the altered expression of long non-coding RNAs (lncRNAs) has been observed during mouse 
osteoclastogenesis, suggesting a physiologic role for lncRNAs in the process [227]. Moreover, in RA 
patients, lncRNA expression has been shown to be altered in cellular types critical for its 
pathophysiology, like peripheral blood mononuclear leukocytes and activated fibroblast-like 
synoviocytes, in comparison to healthy controls [79,213,214]. However, no study has yet examined 
lncRNAs expression in monocytes and osteoclasts of RA patients. Taken this, this research work was 
designed to address this issue and gain further insight on the role of lncRNAs in the cellular 
mechanisms controlling the function of osteoclasts and monocytes, specifically in early arthritis and 
established RA patients.  
To tackle this, an in vitro differentiation protocol of osteoclasts was performed using monocytes 
isolated from early arthritis patients and healthy controls. As described in section 3 of the results, 
we observed a 4-fold increase in the number of fully differentiated osteoclasts in early arthritis 
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patients, when compared to those of healthy controls. These results suggest that peripheral 
monocytes of early arthritis patients appear to be more prone to osteoclastogenesis, which is 
consistent with the increased differentiation of osteoclasts and the imbalance in bone metabolism 
usually documented in RA patients [130]. In this regard, it has been reported that RA patients 
present a higher percentage of CD14+ osteoclast precursors in the blood circulation in comparison 
to healthy controls and that in vitro-derived osteoclasts present lower apoptosis rates than those 
derived from the control group [130]. Altogether, these results suggest that these two factors might 
contribute to the larger number of osteoclasts found in RA patients. Other authors have further 
reported an increased monocyte turnover, along with a reduced circulation time in the blood and 
a most prominent activation of monocytes in the joints of RA patients [228]. These findings indicate 
that there is an increased number of active monocytes in RA, that ultimately leads to increased 
osteoclastogenesis. In addition, the increased bone resorption by osteoclasts that leads to bone 
erosions in rheumatoid arthritis patients might also be due to increased functional activity, and not 
only to increased numbers of circulating precursors [229]. 
It is known that in the inflamed RA joint the formation of immune complexes, in parallel with 
rheumatoid factor production, stimulates monocytes and macrophages to produce TNF- [180]. 
The presence of this and other pro-inflammatory cytokines is known to stimulate osteoclast 
differentiation and activity, and thus, to increase bone resorption in RA [230]. RANKL, a critical 
cytokine in osteoclastogenesis is expressed by both synovial fibroblasts and activated T cells among 
other cell types present in synovial tissues from RA patients [231]. These synovial cells thus 
contribute directly to the expansion of osteoclast precursors and to the formation and activation 
of osteoclasts at sites of bone erosion in RA. As so, the synovial tissue in RA is a source of osteoclasts 
differentiation factors and pro-inflammatory cytokines that foster increased osteoclastogenesis 
and consequently, an increased osteoclastic activity, that ultimately lead to bone erosions in RA 
patients [230,231].  
After obtaining fully differentiated osteoclasts from both early arthritis patients and healthy 
controls, the expression of a panel of lncRNAs was analyzed. From this panel, only NEAT1, GAS5, 
and DANCR were shown to be expressed in the in vitro-derived osteoclasts from both groups. Our 
results showed that these lncRNAs are differentially expressed in osteoclasts of early arthritis 
patients when compared to those of healthy controls (Figure 5). In particular, we observed an 
increased NEAT1 expression and a slightly decreased expression for both GAS5 and DANCR in 
osteoclasts of early arthritis patients when compared to healthy controls. Despite the fact that no 
meaningful statistical analysis could be performed in view of the reduced number of samples 
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collected, our preliminary data suggest to us that the assayed lncRNAs may play a role in the 
increased osteoclastogenesis and/or enhanced osteoclastic activity reported in RA patients.  
Such a proposal is in accordance with previously published studies. A recent report by Cui et al., 
using a mice model (C57BL/10 mice) suggested that EPC (endothelial progenitor cell) ‐ derived 
exosomes could promote osteoclastogenesis through the lncRNA‐MALAT1/miR124 pathway. In this 
report, lncRNA‐MALAT1 was shown to directly bind to miR‐124 and subsequently, to negatively 
control the microRNA activity. Moreover, miR‐124 overexpression was observed to reverse the 
migration and osteoclastic differentiation of bone marrow‐derived macrophages induced by EPC‐
derived exosomes [232]. On the other hand, a study by Dou et al., using RAW264.7 mouse cells as 
osteoclasts precursors for in vitro osteoclastogenesis, reported that most RANKL-dependent gene 
expression was upregulated during osteoclastogenesis and that specific gene expression changes 
were observed at different stages of differentiation [227]. Importantly, the authors profiled the 
expression of lncRNAs, by microarray, during mouse osteoclastogenesis. In comparison to 
unstimulated RAW264.7 cells, they found 1,643 lncRNAs upregulated and 2,705 lncRNAs 
downregulated in pre-osteoclasts. In mature osteoclasts, 1,896 lncRNAs were upregulated and 
2,706 lncRNAs were downregulated. In activated osteoclasts, 2,716 lncRNAs were upregulated and 
3,124 lncRNAs were downregulated [227]. Overall, they reported that at distinct stages of 
osteoclastogenesis, thousands of lncRNAs were differentially expressed compared to the control 
group. A different study with RAW264.7 mouse cells reported that lncRNA-Jak3 and Jak3 co-
expression patterns were significantly upregulated in differentiated osteoclasts, inducing the 
upregulation of the expression of cathepsin K [233]. Finally, it was recently reported by Liu et al., 
that the expression of the lncRNA AK077216 is significantly upregulated during mouse 
osteoclastogenesis, and that the up and downregulation of this lncRNA, respectively, promotes and 
inhibits osteoclast differentiation, bone resorption, and the expression of TRAP related genes [234]. 
These pieces of evidence further support the hypothesis that lncRNAs play a critical role in the 
differentiation and activation of osteoclasts.   
As previously described, monocytes play a key role in modulating the pathophysiological 
mechanisms of RA, besides being the precursor cells for osteoclasts. Therefore, one of the focus of 
this study was to analyze the expression of the selected panel of lncRNAs in these cells. Again, as 
previously with osteoclasts, we only observed the expression of NEAT1, GAS5, and DANCR in 
monocytes of all groups studied. For these lncRNAs, we observed their differential expression in 
monocytes of early arthritis patients and established RA patients when compared to those of 
healthy controls (Figure 4). In particular, monocytes of established RA patients displayed an 
Analysis of lncRNAs expression in monocytes and osteoclasts of rheumatoid arthritis patients 
Inês Abrunhosa Amaral 
 
78 
 
increased expression of NEAT1, a slightly increased expression of GAS5 and a minor decreased 
expression of DANCR, when compared to those of healthy controls. Regarding the monocytes of 
early arthritis patients, we observed an increased expression of NEAT1, a decreased expression of 
GAS5 and no relevant expression variation for DANCR, when compared to healthy controls. Despite 
the fact that the observed expression variations were not statistically significant, these results 
suggest to us that these particular lncRNAs could play a role in monocyte biology in RA, perhaps, 
contributing to the increased number of blood circulating monocytes and/or to the enhanced 
monocyte proinflammatory and immunomodulatory activities reported in RA patients. 
LncRNAs have been recently predicted to constitute important regulators of the human innate 
immune response, and in particular, of the function of human monocytes [235]. But, although there 
are some publications describing the profile of lncRNAs expression in human monocytes [236,237], 
their functional role in these cells remains largely unclear. A recent study by Riege et al. concluded 
that lncRNA expression is affected in human monocytes in response to bacterial and fungal 
infections and that some lncRNAs stimulate the activation of specific immunomodulatory activity 
in monocytes [238]. Moreover, evidence indicates that the abnormal expression of lncRNAs in 
monocyte-derived dendritic cells may be involved in the pathological processes of systemic lupus 
erythematosus (SLE), with potential value for the assessment of disease activity in SLE accordingly 
to levels of expression of some lncRNAs [239].  
When considering our data on lncRNA expression, differential expression of NEAT1, GAS5 and 
DANCR were further detected between monocytes and osteoclasts of both healthy controls and 
early arthritis patients (Figures 6 and 7). In healthy controls, the expression of all 3 lncRNAs was 
increased in osteoclasts, when compared to monocytes. Regarding early arthritis patients, we 
observed a decreased expression of NEAT1 and a tendency for increased expression of both GAS5 
and DANCR.  Although a meaningful statistical analysis could not be performed taken the reduced 
number of samples analyzed for osteoclasts, our results collectively suggested to us that these 
lncRNAs can possibly play a role in the osteoclastogenesis process, in both physiological and 
pathological settings. This proposal is in agreement with the previously mentioned study by Dou et 
al. where a differential expression of several lncRNAs was reported during different time points of 
mouse osteoclastogenesis [227].   
In the present report, we have observed that NEAT1 expression was upregulated in both monocytes 
and osteoclasts of early arthritis patients and established RA patients when compared to healthy 
controls. As far as we know, our study is the first to report similar findings. In fact, until now, no 
published work has particularly analyzed the expression of NEAT1 in monocytes and osteoclasts, in 
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the context of rheumatoid arthritis patients. Still, a recent study by Shui et al. reported a significant 
upregulation of NEAT1 in PBMCs of RA patients, which are in accordance with our findings [240]. 
The authors have further performed an in vitro differentiation of CD4+ T cells isolated from RA 
patients into Th17 cells and showed that NEAT1 was also upregulated in these Th17 cells [240]. 
These are proinflammatory T cells with a critical role in RA pathogenesis, as they produce IL-17, one 
of the most important proinflammatory cytokines in RA [241]. Moreover, knockdown of NEAT1 
positively inhibited Th17/CD4+ T cell differentiation through reducing the signal transducer and 
activator of transcription 3 (STAT3) protein level [240]. In such a way, lncRNA NEAT1 should play an 
important role in RA pathogenesis and should, therefore, be considered as a potential therapeutical 
target for RA treatment [240]. In addition, NEAT1 was shown to be predominantly expressed in 
human monocytes and importantly, its expression was shown to be abnormally increased in both 
PBMCs and monocytes of systemic lupus erythematosus (SLE) patients [224]. Furthermore, Zhang 
et al. reported a positive correlation between NEAT1 expression levels and clinical disease activity 
in SLE patients [224]. Overall, the increased NEAT1 expression could be a potential contributor to 
the elevated production of several cytokines and chemokines in SLE patients [224].  
Although the pieces of evidence are still scarce, these studies clearly suggest a crucial role for NEAT1 
in regulating the inflammatory processes in autoimmune diseases such as RA and SLE. Beyond this, 
other functions have been proposed for this lncRNA in human diseases. Namely, NEAT1 has been 
shown to: (i) promote the proliferation and metastasis in breast cancer [242]; (ii) promote 
tumorigenesis in colorectal cancer [243]; (iii) predict various malignant tumor lymph node 
metastasis [244] and (iv) correlates with increased disease risk, elevated severity, and unfavorable 
prognosis as well as higher expression of pro-inflammatory cytokines in sepsis patients [245]. 
Concerning GAS5 lncRNA, when compared to healthy controls, our results showed that its 
expression is downregulated in both monocytes and osteoclasts of early arthritis patients and 
slightly upregulated in monocytes of established RA patients. To our knowledge, the current study 
is the first to report these findings. Until now, no published reports have investigated the expression 
of GAS5 in monocytes and osteoclasts, in the context of rheumatoid arthritis patients. However, a 
recent study by Li et al. reported that GAS5 expression is significantly decreased in the synovial 
tissues and fibroblast-like synoviocytes (FLSs) of RA patients, suggesting that GAS5 downregulation 
could be a pathological feature of RA probably by inhibiting FLSs apoptosis [221]. Through a series 
of experiments, the authors hypothesized that GAS5 overexpression could be a viable tool for 
inhibiting FLSs proliferation in RA [221]. These results could support our findings since early arthritis 
patients are non-treated and represent the first and often most severe presentation of the disease, 
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with the downregulation of GAS5. Additionally, GAS5 expression in monocytes of established RA 
patients was observed to be significantly negatively correlated with the number of tender joints in 
these patients. This result would suggest that a reduction in the number of tender joints in RA 
patients is associated with a higher expression of GAS5 in monocytes. However, despite the 
obtained statistical significance, a closer inspection of the distribution of the data (Figure 8) allowed 
us to understand that most of the data are highly deviated from the linear regression line obtained 
with them, i.e., that this is not a robust correlation. Still, we propose that the slight upregulation of 
GAS5 in the monocytes of RA patients could be related with a decreased degree of inflammation in 
RA joints, suggesting a role for GAS5 as a modulator of the immunoinflammatory pathways in RA.  
Moreover, it was reported by Song et al. that GAS5 is upregulated in chondrocytes of osteoarthritis 
(OA) patients [246]. This upregulation was found to be associated with increased activation of 
several MMPs, suggesting that GAS5 plays a role in OA pathogenesis [246]. Another study by Guo 
et al. reported that GAS5 acts as a tumor suppressor lncRNA in endometrial cancer, by significantly 
enhancing the expression of PTEN to promote cancer cell apoptosis [247]. Data published by 
Sugatani et al. demonstrated multiple roles for PTEN in RANKL-induced osteoclast differentiation 
and OPN-stimulated cell migration, in RAW 264.7 osteoclast precursors [248]. The authors showed 
that PTEN overexpression suppressed RANKL-mediated osteoclast differentiation and OPN 
stimulated cell migration [248]. Based on these pieces of evidence we can propose that GAS5 could 
play important roles in RA pathogenesis, on one hand, by modulating FLSs survival and migration, 
and on the other, by modulating osteoclast differentiation and migration. Through these effects, 
GAS5 may critically contribute to cartilage and bone destruction, typically observed in RA.  
Beyond rheumatic disease, GAS5 has been observed to be implicated in other pathologies. 
Importantly, this lncRNA has been reported to be implicated and aberrantly expressed in a variety 
of human cancers. In a recently published study by Cheng et al., reduced GAS5 levels were 
significantly associated with advanced clinical stage and lymph node metastasis in colorectal cancer 
(CRC) patients [249]. Additionally, GAS5 overexpression suppressed CRC cell proliferation and 
promoted cellular apoptosis [249]. Accordingly, several findings indicate that GAS5 expression is 
decreased in other cancers and that its overexpression functions as a tumor suppressor in prostate 
cancer [250], osteosarcoma [251] and ovarian cancer [252]. 
Regarding DANCR, our results showed that this lncRNA expression is slightly downregulated in both 
monocytes of established RA patients and osteoclasts of early arthritis patients when compared to 
healthy controls. Interestingly, no differences in DANCR expression were found in monocytes of 
early arthritis patients and healthy controls. To our knowledge, this study is the first to report these 
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findings. Until now, there are no published reports where the expression of DANCR was thoroughly 
inspected in monocytes and osteoclasts, in the context of rheumatoid arthritis patients. This lncRNA 
has instead been implicated in the pathogenesis of osteoarthritis. A study by Xiao et al. recently 
reported that DANCR is differently expressed in human knee osteoarthritis patients [253]. In 
addition, Zhang et al. showed that the expression of DANCR was significantly increased in OA 
patients, and further implicated this lncRNA in promoting the proliferation, inflammation, and 
reduced cell apoptosis of chondrocytes in OA [254]. Consistently, similar results were reported by 
Fan et al. [255]. These pieces of evidence place DANCR as a critical therapeutic target to tackle OA 
and moreover, as a potential mediator in the pathological mechanisms underlying other chronic 
joint diseases, such as RA. Interestingly, however, in contrast to our results, an upregulation of 
DANCR in the blood monocytes of postmenopausal women with increased risk for osteoporosis was 
reported by Tong et al. to be correlated with increased levels of IL-6 and TNF-α in these patients. 
These results led the authors to suggest that DANCR could be involved in the pathology of 
osteoporosis [256]. 
Beyond the scope of rheumatology, several recently published studies have highlighted the role of 
DANCR in promoting tumor progression [257–260]. Gao et al. reported that ovarian cancers 
displayed a significantly higher expression of DANCR in comparison to that detected in the 
corresponding normal tissues [257]. Upon DANCR overexpression, the authors have importantly 
shown that the proliferation, invasion, and migration of ovarian cancer cells were markedly 
increased [257]. Similar findings were reported in a study by Tao et al. in breast cancer patients: (i) 
breast cancer samples displayed a similar upregulation of DANCR expression and (ii) higher DANCR 
expression levels were correlated to a poorer prognosis [258]. 
As mentioned in the Results section and contrary to our expectations, we did not detect the 
expression of Meg3, Meg9, HOTAIR, H19, and Sox2OT lncRNAs, in both monocytes and osteoclasts 
of early arthritis and RA patients, and healthy controls. Still, the expression of these lncRNAs was 
measurable in PBMCs of healthy controls (data not shown). From these results, our data on HOTAIR 
expression were the most unexpected ones taken that this lncRNA was previously reported to be 
expressed in differentiated osteoclasts of RA patients [223]. This data discrepancy may be due to 
the use of distinct differentiation protocols for in vitro osteoclastogenesis.  
The role of lncRNAs in RA pathogenesis was explored by Jiang et al., in a study that aimed to identify 
the expressed lncRNAs that could be relevant to adjuvant-induced arthritis (AA) in rats and to 
explore the possible molecular mechanisms of RA pathogenesis [261]. The results revealed that 
multiple clusters of lncRNAs were uniquely expressed in AA rats compared with controls, which 
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implies that these differentially expressed lncRNAs in AA rats might have a vital role in RA 
development [261]. 
Summarizing, increasing evidence indicates that lncRNAs function as key modulators of the 
immunoinflammatory pathways in RA, as well as of pathological mechanisms of monocytes and 
osteoclasts, suggesting that they could be putative therapeutic targets. Dysregulation of the 
expression levels of several lncRNAs has been pinpointed as possible components of the 
pathological mechanisms underlying rheumatoid arthritis [79,212–214,262,263]. The present 
research work contributes to this field by providing the first data on the expression of specific 
lncRNAs in both monocytes and osteoclasts of early arthritis and established RA patients. 
Nevertheless, further studies will be needed to fully understand the involvement of lncRNAs, as 
well as, their specific mechanisms of action in RA pathogenesis.  
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FINAL REMARKS 
 
In the past decade, long non-coding RNAs have emerged as important players in gene regulation 
and in an increasing diversity of scientific areas, including, disease pathogenesis. In this regard, 
research on lncRNAs represents nowadays a new frontier in the study of human diseases [185–
187]. 
In this study, we present preliminary data that suggest, for the first time, differential expression of 
several lncRNAs in monocytes and osteoclasts of rheumatoid arthritis patients. Regarding NEAT1, 
our results are suggestive of an upregulation of this lncRNA in early arthritis and established RA, 
leading us to propose NEAT1 to be closely associated with rheumatoid arthritis pathogenesis, most 
probably as a key modulator of immunoinflammatory processes in RA. In what concerns GAS5, our 
results led us to propose that the slight upregulation of this lncRNA observed in the monocytes of 
RA patients could be related with a decreased degree of inflammation in RA joints, suggesting a 
role for GAS5 as a modulator of the immunoinflammatory pathways in RA. Finally, a slight 
downregulation of DANCR was observed in both monocytes of established RA patients and 
osteoclasts of early arthritis patients. Altogether, these results led us to suggest that DANCR may 
possibly play a role in the pathological mechanism of chronic joint inflammation in RA. 
Inflammatory bone resorption mediated by osteoclasts is a major cause of morbidity and disability 
in many inflammatory disorders, including rheumatoid arthritis. The mechanisms that regulate 
osteoclastogenesis and bone resorption in inflammatory settings are complex and have not been 
fully elucidated [264]. With this study, we provide preliminary data that collectively suggest that 
the studied lncRNAs might play a significant role in the altered bone metabolism present in RA 
patients, perhaps by modulating immunoinflammatory pathways that impact on chronic joint 
inflammation and bone erosion. Although a limited study on the role of lncRNA in rheumatoid 
arthritis is available, an increasing number of authors recognize the potential of these RNAs in RA 
pathogenesis [79,261–263]. In fact, it is already known that long noncoding RNAs are involved in 
gene regulation in the immune system [203] and the transcriptional control of inflammatory 
responses [204]. Moreover, lncRNAs participate in the regulation of both the innate and adaptative 
immune responses [205–207]. Additionally, these RNAs have been pinpointed as key players and 
potential therapeutic targets in autoimmune diseases [209]. 
As future perspectives, we highlight the need for further research work on the functional roles of 
lncRNAs in the pathogenesis of rheumatoid arthritis. A major limitation of our study concerns the 
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reduced number of samples collected that may have precluded us from obtaining statistically 
significant results. To circumvent this, a larger cohort of RA patients should obviously be sampled 
in the future. In addition, this study may need some strategic adjustments, some of which have 
already started to be implemented during the course of the current work. Our initial aim was to 
analyze lncRNA expression in both monocytes and osteoclasts of all study groups. However, along 
the way, we realized that despite collecting a significant amount of blood, it was not possible to 
isolate enough monocytes to simultaneously collect a sufficient amount of total RNA for studying 
lncRNA expression in these cells and also differentiate them into osteoclasts. To circumvent this, 
we figured that this expression study could be performed in separate moments for monocytes and 
osteoclasts. Thereof and for improving sample collection, we concentrated our attention on 
addressing lncRNA expression in monocytes. Alternatively, to overcome the limitation of the 
reduced amount of total RNA collected for some samples, one hypothesis may also be to reduce 
the amount of total RNA used for cDNA synthesis. A different approach to bypass these problems 
in the future may as well be to employ a transcriptomic analysis for lncRNA expression such as, with 
microarrays or RNA sequencing. When in place, these strategies will also provide us with a full and 
comprehensive analysis of lncRNA expression in monocytes and osteoclasts in RA. 
Still, the current work provided a first study of the expression of lncRNAs in monocytes and 
osteoclasts of RA patients that will pave the way for understanding the role of these RNAs in RA. 
Such insight will be pivotal for fully exploring the vast potential use of lncRNAs as therapeutic 
targets in RA and other immune-mediated diseases.  
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